https://psychopharmacologyinstitute.com/publication/the-role-of-genetic-testing-in-psychiatry-mastering-adult-adhd-a-comprehensive-clinical-guide-29362025-06-16never0.5https://psychopharmacologyinstitute.com/publication/an-update-on-bipolar-mania-algorithm-understanding-postpartum-mood-disorders-a-comprehensive-guide-29292025-05-12never0.5https://psychopharmacologyinstitute.com/publication/pharmacologic-management-of-opioid-use-disorder-use-of-psychedelic-drugs-in-psychiatry-29252025-04-28never0.5https://psychopharmacologyinstitute.com/publication/ketamine-guide-pharmacology-indications-dosing-guidelines-and-adverse-effects-29242025-07-17never0.5https://psychopharmacologyinstitute.com/publication/esketamine-guide-pharmacology-indications-dosing-guidelines-and-adverse-effects-29232025-06-12never0.5https://psychopharmacologyinstitute.com/publication/mirtazapine-guide-pharmacology-indications-dosing-guidelines-and-adverse-effects-29222025-05-14never0.5https://psychopharmacologyinstitute.com/publication/tms-in-psychiatry-innovations-and-best-practices-strategies-for-successful-benzodiazepine-deprescribing-29212025-04-28never0.5https://psychopharmacologyinstitute.com/publication/bupropion-guide-pharmacology-indications-dosing-guidelines-and-adverse-effects-29202025-04-09never0.5https://psychopharmacologyinstitute.com/publication/use-of-maoi-in-clinical-practice-interview-29152025-07-25never0.5https://psychopharmacologyinstitute.com/publication/vortioxetine-guide-pharmacology-indications-dosing-guidelines-and-adverse-effects-29122025-04-09never0.5https://psychopharmacologyinstitute.com/publication/managing-catatonia-from-clinical-assessment-to-effective-intervention-29112025-06-30never0.5https://psychopharmacologyinstitute.com/publication/levomilnacipran-guide-pharmacology-indications-dosing-guidelines-and-adverse-effects-29032025-04-09never0.5https://psychopharmacologyinstitute.com/publication/duloxetine-guide-pharmacology-indications-dosing-guidelines-and-adverse-effects-29022025-04-09never0.5https://psychopharmacologyinstitute.com/publication/2024-in-review-new-fda-approvals-in-psychiatry-29012025-04-09never0.5https://psychopharmacologyinstitute.com/publication/desvenlafaxine-guide-pharmacology-indications-dosing-guidelines-and-adverse-effects-29002025-04-09never0.5https://psychopharmacologyinstitute.com/publication/lithium-how-to-manage-dosage-and-side-effects-28892025-05-13never0.5https://psychopharmacologyinstitute.com/publication/venlafaxine-guide-pharmacology-indications-dosing-guidelines-and-adverse-effects-28882025-04-09never0.5https://psychopharmacologyinstitute.com/publication/pharmacotherapy-of-eating-disorders-an-update-28832025-03-26never0.5https://psychopharmacologyinstitute.com/publication/use-of-long-acting-injectable-antipsychotics-in-schizophrenia-28812025-05-30never0.5https://psychopharmacologyinstitute.com/publication/managing-side-effects-of-antipsychotics-what-every-psychiatrist-should-know-28802025-02-27never0.5https://psychopharmacologyinstitute.com/publication/prescribing-in-pregnancy-what-every-psychiatrist-should-know-interview-28782025-05-30never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-76-28742025-07-01never0.5https://psychopharmacologyinstitute.com/publication/the-role-of-genetic-testing-in-psychiatry-interview-28732025-05-14never0.5https://psychopharmacologyinstitute.com/publication/understanding-postpartum-mood-disorders-a-comprehensive-guide-interview-28722025-06-23never0.5https://psychopharmacologyinstitute.com/publication/mastering-adult-adhd-a-comprehensive-clinical-guide-interview-28702025-06-23never0.5https://psychopharmacologyinstitute.com/publication/pharmacologic-management-of-opioid-use-disorder-interview-28692025-03-04never0.5https://psychopharmacologyinstitute.com/publication/an-update-on-bipolar-mania-algorithm-interview-28682025-06-23never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-75-28672025-05-28never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-74-28662025-04-23never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-73-28652025-03-31never0.5https://psychopharmacologyinstitute.com/publication/rethinking-depression-treatment-an-update-of-canmats-guidelines-28642025-01-30never0.5https://psychopharmacologyinstitute.com/publication/apa-annual-meeting-highlights-broad-spectrum-micronutrient-treatments-and-best-practices-for-benzodiazepine-use-28632024-06-01never0.5https://psychopharmacologyinstitute.com/publication/iloperidone-for-bipolar-i-disorder-principles-of-psychodynamic-psychopharmacology-and-tms-in-psychiatry-28602024-04-30never0.5https://psychopharmacologyinstitute.com/publication/fda-verdict-on-roluperidone-the-role-of-psychopharmacology-in-autism-spectrum-disorder-and-management-of-behavioral-emergencies-28592024-03-27never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-53-quick-take-vol-54-quick-take-vol-55-quick-take-vol-56-quick-take-vol-57-28582024-04-18never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-48-quick-take-vol-49-quick-take-vol-50-quick-take-vol-51-quick-take-vol-52-28572024-04-18never0.5https://psychopharmacologyinstitute.com/publication/parasomnias-triggered-by-antidepressant-medications-broad-spectrum-micronutrients-in-psychiatry-tic-disorders-in-children-and-adolescents-depression-anxiety-and-delirium-in-patients-with-cancer-nociceptive-pain-syndromes-focus-on-fibromyalgia-28562024-04-18never0.5https://psychopharmacologyinstitute.com/publication/psychosis-and-schizophrenia-in-children-and-adolescents-updates-on-geriatric-psychopharmacology-atypical-psychopharmacologic-strategies-for-children-and-adolescents-algorithm-for-the-pharmacotherapy-of-ocd-managing-explosive-behavior-in-youth-28552024-04-18never0.5https://psychopharmacologyinstitute.com/publication/natural-medication-in-psychiatry-focus-on-versatile-agents-and-combination-strategies-navigating-insomnia-in-major-depressive-disorder-advances-in-management-quick-take-vol-47-28542024-04-18never0.5https://psychopharmacologyinstitute.com/publication/perinatal-treatment-of-bipolar-disorder-psychodynamic-psychopharmacology-from-biomedical-approaches-to-patient-relationships-management-of-behavioral-and-psychological-symptoms-of-dementia-interview-28532024-04-18never0.5https://psychopharmacologyinstitute.com/publication/nociplastic-pain-syndromes-focus-on-fibromyalgia-broad-spectrum-micronutrients-bsms-for-mental-health-what-you-need-to-know-for-clinical-use-antipsychotic-switching-intersection-of-art-and-science-interview-28522024-04-18never0.5https://psychopharmacologyinstitute.com/publication/depression-anxiety-and-delirium-in-patients-with-cancer-clozapine-management-and-challenges-ocd-in-children-and-adolescents-interview-28512024-04-18never0.5https://psychopharmacologyinstitute.com/publication/parasomnias-triggered-by-sedative-hypnotics-sleepwalking-and-sleep-related-eating-disorder-tic-disorders-in-children-and-adolescents-pharmacologic-management-of-bpd-recent-developments-interview-28502024-04-18never0.5https://psychopharmacologyinstitute.com/publication/broad-spectrum-micronutrients-bsm-for-mental-health-context-for-considering-the-role-of-psychopharmacology-in-autism-spectrum-disorder-pharmacotherapies-for-stimulant-use-disorder-interview-28492024-04-18never0.5https://psychopharmacologyinstitute.com/publication/discontinuation-of-aducanumab-nociceptive-pain-syndromes-and-lamotrigine-indications-and-side-effects-28482024-02-23never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-72-28472025-02-27never0.5https://psychopharmacologyinstitute.com/publication/prescribing-in-pregnancy-what-every-clinician-should-know-28462025-01-10never0.5https://psychopharmacologyinstitute.com/publication/understanding-benzodiazepine-prescribing-a-clinicians-guide-interview-28442025-06-23never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-71-28432025-02-05never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-70-28422024-12-31never0.5https://psychopharmacologyinstitute.com/publication/upcoming-psychiatric-drugs-for-2024-anxiety-and-delirium-in-patients-with-cancer-and-psychodynamic-psychopharmacology-28392024-01-17never0.5https://psychopharmacologyinstitute.com/publication/2023-in-review-fda-approvals-in-psychiatry-tic-disorders-in-youth-and-insomnia-in-major-depressive-disorder-28382024-01-02never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-69-28372024-11-30never0.5https://psychopharmacologyinstitute.com/publication/tms-in-psychiatry-innovations-and-best-practices-interview-28362025-06-23never0.5https://psychopharmacologyinstitute.com/publication/mastering-adult-adhd-a-comprehensive-clinical-guide-28352024-09-30never0.5https://psychopharmacologyinstitute.com/publication/december-2023-newsletter-fda-issues-warning-on-compounded-ketamine-products-broad-spectrum-micronutrients-and-natural-medication-in-psychiatry-28342023-11-29never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-68-28312024-10-29never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-67-28302024-10-01never0.5https://psychopharmacologyinstitute.com/publication/lamotrigine-from-current-indications-to-cardiac-side-effects-interview-28292025-06-23never0.5https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-of-agitation-managing-behavioral-emergencies-interview-28282025-06-23never0.5https://psychopharmacologyinstitute.com/publication/the-role-of-genetic-testing-in-psychiatry-28272024-11-28never0.5https://psychopharmacologyinstitute.com/publication/understanding-postpartum-mood-disorders-a-comprehensive-guide-28262024-10-25never0.5https://psychopharmacologyinstitute.com/publication/november-2023-newsletter-gepirone-for-mdd-parasomnias-triggered-by-antidepressant-medication-and-psychodynamic-psychopharmacology-28252023-11-29never0.5https://psychopharmacologyinstitute.com/publication/october-2023-newsletter-suicide-prevention-managing-explosive-behavior-in-youth-and-perinatal-treatment-of-bipolar-disorder-28242023-09-29never0.5https://psychopharmacologyinstitute.com/publication/fluvoxamine-practical-guide-pharmacology-indications-dosing-guidelines-and-adverse-effects-28232024-10-25never0.5https://psychopharmacologyinstitute.com/publication/fluoxetine-practical-guide-pharmacology-indications-dosing-guidelines-and-adverse-effects-28222024-10-25never0.5https://psychopharmacologyinstitute.com/publication/september-2023-newsletter-zuranolone-for-postpartum-depression-algorithm-for-the-pharmacotherapy-of-ocd-and-bsms-for-mental-health-28212023-08-31never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-66-28182024-08-27never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-65-28172024-08-13never0.5https://psychopharmacologyinstitute.com/publication/perinatal-treatment-of-bipolar-disorder-interview-28152025-06-23never0.5https://psychopharmacologyinstitute.com/publication/an-update-on-bipolar-mania-algorithm-28142024-08-13never0.5https://psychopharmacologyinstitute.com/publication/use-of-psychedelic-drugs-in-psychiatry-28132024-08-30never0.5https://psychopharmacologyinstitute.com/publication/august-2023-newsletter-donanemab-for-alzheimers-disease-atypical-psychopharmacologic-strategies-for-youth-and-pharmacologic-therapies-for-fibromyalgia-28122023-07-28never0.5https://psychopharmacologyinstitute.com/publication/july-2023-newsletter-evidence-based-mental-health-apps-updates-on-geriatric-psychopharmacology-and-clozapine-management-and-challenges-28112023-06-29never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-64-28092024-08-13never0.5https://psychopharmacologyinstitute.com/publication/navigating-insomnia-and-other-sleep-disorders-in-depression-interview-28082025-06-23never0.5https://psychopharmacologyinstitute.com/publication/pharmacologic-management-of-opioid-use-disorder-28072024-08-13never0.5https://psychopharmacologyinstitute.com/publication/june-2023-newsletter-apa-annual-meeting-farewell-to-dr-phelps-psychosis-in-youth-and-depression-anxiety-and-delirium-in-patients-with-cancer-28062023-08-29never0.5https://psychopharmacologyinstitute.com/publication/may-2023-newsletter-guidelines-for-managing-catatonia-management-of-behavioral-and-psychological-symptoms-of-dementia-and-tic-disorders-among-youth-28052023-04-26never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-63-28022024-08-13never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-62-28012024-08-13never0.5https://psychopharmacologyinstitute.com/publication/psychodynamic-psychopharmacology-interview-28002025-06-23never0.5https://psychopharmacologyinstitute.com/publication/exploring-the-clinical-implications-of-broad-spectrum-micronutrient-treatment-interview-27992025-06-23never0.5https://psychopharmacologyinstitute.com/publication/strategies-for-successful-benzodiazepine-deprescribing-27982024-08-13never0.5https://psychopharmacologyinstitute.com/publication/understanding-benzodiazepine-prescribing-a-clinicians-guide-27972024-08-13never0.5https://psychopharmacologyinstitute.com/publication/april-2023-newsletter-apa-guidelines-for-treating-eating-disorders-antipsychotic-switching-and-parasomnias-triggered-by-sedative-hypnotics-27962023-08-29never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-61-27942024-08-13never0.5https://psychopharmacologyinstitute.com/publication/nociceptive-pain-syndromes-focus-on-fibromyalgia-interview-27932024-08-13never0.5https://psychopharmacologyinstitute.com/publication/tms-in-psychiatry-innovations-and-best-practices-27922024-08-13never0.5https://psychopharmacologyinstitute.com/publication/lamotrigine-from-current-indications-to-cardiac-side-effects-27912025-06-20never0.5https://psychopharmacologyinstitute.com/publication/march-2023-newsletter-kisspeptin-for-hypoactive-sexual-desire-disorder-ocd-in-children-and-adolescents-and-the-role-of-psychopharmacology-in-asd-27902023-03-01never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-20-27892024-08-13never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-60-27882024-08-13never0.5https://psychopharmacologyinstitute.com/publication/clozapine-management-and-challenges-interview-27872025-01-30never0.5https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-of-agitation-managing-behavioral-emergencies-27862024-08-13never0.5https://psychopharmacologyinstitute.com/publication/february-2023-newsletter-lecanemab-approval-for-alzheimers-disease-pharmacologic-management-of-bpd-and-broad-spectrum-micronutrients-bsm-for-mental-health-27852023-02-25never0.5https://psychopharmacologyinstitute.com/publication/psychodynamic-psychopharmacology-alliance-communication-and-psychotherapy-skills-27842024-08-13never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-19-27832024-08-13never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-18-27822024-08-13never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-17-27812024-08-15never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-16-27802024-08-15never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-15-27792024-08-15never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-59-27782024-08-13never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-58-27772024-08-13never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-57-27762024-08-15never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-56-27752024-08-15never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-55-27742024-08-15never0.5https://psychopharmacologyinstitute.com/publication/depression-anxiety-and-delirium-in-patients-with-cancer-interview-27732025-02-26never0.5https://psychopharmacologyinstitute.com/publication/tic-disorders-in-children-and-adolescents-interview-27722024-08-14never0.5https://psychopharmacologyinstitute.com/publication/the-role-of-psychopharmacology-in-autism-spectrum-disorder-interview-27712025-06-23never0.5https://psychopharmacologyinstitute.com/publication/broad-spectrum-micronutrients-in-psychiatry-interview-27702024-08-14never0.5https://psychopharmacologyinstitute.com/publication/parasomnias-triggered-by-antidepressant-medications-rem-sleep-behavior-disorder-and-restless-legs-syndrome-interview-27692024-08-14never0.5https://psychopharmacologyinstitute.com/publication/natural-medication-in-psychiatry-focus-on-versatile-agents-and-combination-strategies-27682024-08-14never0.5https://psychopharmacologyinstitute.com/publication/psychodynamic-psychopharmacology-from-biomedical-approaches-to-patient-relationships-27672024-08-14never0.5https://psychopharmacologyinstitute.com/publication/perinatal-treatment-of-bipolar-disorder-27662024-08-14never0.5https://psychopharmacologyinstitute.com/publication/navigating-insomnia-in-major-depressive-disorder-advances-in-management-27652024-10-07never0.5https://psychopharmacologyinstitute.com/publication/2022-in-review-fda-approvals-in-psychiatry-pharmacotherapies-for-stimulant-use-disorder-and-parasomnias-triggered-by-antidepressant-medications-27642023-01-06never0.5https://psychopharmacologyinstitute.com/publication/psychotropic-drug-adherence-interview-psychotropic-drugs-in-lactation-interview-psychotic-depression-psychopharmacology-algorithm-interview-medicinal-cannabis-and-the-psychiatric-patient-interview-and-psychosis-first-episode-interview-27632024-10-25never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-42-quick-take-vol-43-quick-take-vol-44-quick-take-vol-45-and-quick-take-vol-46-27622024-10-25never0.5https://psychopharmacologyinstitute.com/publication/parasomnias-triggered-by-antidepressant-medications-broad-spectrum-micronutrients-bsm-for-mental-health-and-obsessive-compulsive-and-related-disorders-interview-27602023-03-31never0.5https://psychopharmacologyinstitute.com/publication/natural-medications-in-child-and-adolescent-psychiatry-managing-some-unique-nonhematologic-adverse-effects-of-clozapine-and-quick-take-vol-41-27592023-03-31never0.5https://psychopharmacologyinstitute.com/publication/atypical-psychopharmacologic-strategies-for-children-and-adolescents-algorithm-for-the-pharmacotherapy-of-obsessive-compulsive-disorder-and-quick-take-vol-40-27582023-03-31never0.5https://psychopharmacologyinstitute.com/publication/managing-explosive-behavior-in-children-and-adolescents-updates-on-geriatric-psychopharmacology-and-quick-take-vol-39-27572023-03-31never0.5https://psychopharmacologyinstitute.com/publication/december-2022-newsletter-naloxone-available-otc-assessment-and-management-of-fep-and-managing-nonhematologic-adverse-effects-of-clozapine-27562022-11-29never0.5https://psychopharmacologyinstitute.com/publication/november-2022-newsletter-national-shortage-of-adderall-medicinal-cannabis-and-the-psychiatric-patient-and-natural-medications-in-youth-27552023-08-30never0.5https://psychopharmacologyinstitute.com/publication/october-2022-newsletter-the-saint-neuromodulation-system-for-mdd-and-the-psychopharmacology-algorithms-for-psychotic-depression-and-obsessive-compulsive-disorder-27542023-08-29never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-14-27532024-08-15never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-13-27522024-08-15never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-12-27512024-08-15never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-11-27502024-08-15never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-10-27492024-08-15never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-09-27482024-08-15never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-08-27472024-08-15never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-07-27462024-08-15never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-06-27452024-08-15never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-05-27442024-08-15never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-04-27432024-08-15never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-03-27422024-08-15never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-02-27412024-08-15never0.5https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-01-27402024-08-15never0.5https://psychopharmacologyinstitute.com/publication/september-2022-newsletter-dextromethorphan-hbr-bupropion-hci-for-treating-mdd-atypical-psychopharmacologic-strategies-for-children-and-adolescents-and-use-of-psychotropic-drugs-in-lactation-27392022-08-31never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-54-27382024-08-15never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-53-27372024-08-15never0.5https://psychopharmacologyinstitute.com/publication/managing-explosive-behavior-in-youth-interview-27362024-08-14never0.5https://psychopharmacologyinstitute.com/publication/algorithm-for-the-pharmacotherapy-of-obsessive-compulsive-disorder-interview-27352024-08-14never0.5https://psychopharmacologyinstitute.com/publication/nociplastic-pain-syndromes-focus-on-fibromyalgia-27342024-08-27never0.5https://psychopharmacologyinstitute.com/publication/clozapine-management-and-challenges-27332024-08-27never0.5https://psychopharmacologyinstitute.com/publication/august-2022-newsletter-introducing-the-988-suicide-and-crisis-lifeline-updates-on-geriatric-psychopharmacology-and-psychotropic-drug-adherence-27322022-08-01never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-52-27312024-08-15never0.5https://psychopharmacologyinstitute.com/publication/atypical-psychopharmacologic-strategies-for-children-and-adolescents-interview-27302024-08-14never0.5https://psychopharmacologyinstitute.com/publication/broad-spectrum-micronutrients-bsms-for-mental-health-what-you-need-to-know-for-clinical-use-27292024-08-14never0.5https://psychopharmacologyinstitute.com/publication/july-2022-newsletter-news-on-pimavanserin-for-alzheimers-disease-psychosis-managing-explosive-behavior-in-children-and-adolescents-and-management-of-delirium-27282022-07-01never0.5https://psychopharmacologyinstitute.com/publication/june-2022-newsletter-apa-annual-meeting-psychosis-and-schizophrenia-in-children-and-adolescents-and-use-of-psychotropics-in-patients-with-hepatic-issues-27272022-05-31never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-51-27262024-08-15never0.5https://psychopharmacologyinstitute.com/publication/updates-on-geriatric-psychopharmacology-interview-27252025-04-29never0.5https://psychopharmacologyinstitute.com/publication/depression-anxiety-and-delirium-in-patients-with-cancer-27242024-08-14never0.5https://psychopharmacologyinstitute.com/publication/may-2022-newsletter-the-problem-of-clozapine-rems-management-of-behavioral-and-psychological-symptoms-of-dementia-and-the-psychopharmacology-of-feeding-and-eating-disorders-27232022-04-29never0.5https://psychopharmacologyinstitute.com/publication/april-2022-newsletter-cariprazine-as-an-adjunctive-treatment-of-mdd-antipsychotic-switching-the-intersection-of-art-and-science-and-gad-psychopharmacology-algorithm-27102023-08-29never0.5https://psychopharmacologyinstitute.com/publication/march-2022-newsletter-cdc-proposed-clinical-practice-guideline-for-prescribing-opioids-ocd-in-children-and-adolescents-and-obsessive-compulsive-and-related-disorders-27092022-02-28never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-50-27082024-08-15never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-49-27072024-08-15never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-48-27062024-08-15never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-47-27052024-08-15never0.5https://psychopharmacologyinstitute.com/publication/psychosis-and-schizophrenia-in-children-and-adolescents-interview-27042024-08-14never0.5https://psychopharmacologyinstitute.com/publication/management-of-behavioral-and-psychological-symptoms-of-dementia-interview-27032024-08-14never0.5https://psychopharmacologyinstitute.com/publication/antipsychotic-switching-intersection-of-art-and-science-interview-27022024-08-14never0.5https://psychopharmacologyinstitute.com/publication/ocd-in-children-and-adolescents-interview-27012024-08-14never0.5https://psychopharmacologyinstitute.com/publication/tic-disorders-in-children-and-adolescents-27002024-08-14never0.5https://psychopharmacologyinstitute.com/publication/parasomnias-triggered-by-sedative-hypnotics-sleepwalking-and-sleep-related-eating-disorder-26982024-08-14never0.5https://psychopharmacologyinstitute.com/publication/february-2022-newsletter-daridorexant-for-insomnia-pharmacologic-management-of-bpd-and-what-clinicians-need-to-know-about-alcohol-use-disorder-26972022-02-01never0.5https://psychopharmacologyinstitute.com/publication/january-2022-newsletter-dsm-5-tr-is-coming-pharmacotherapies-for-stimulant-use-disorder-and-premenstrual-mood-syndromes-26962021-12-31never0.5https://psychopharmacologyinstitute.com/publication/the-role-of-psychopharmacology-in-autism-spectrum-disorder-26952024-08-14never0.5https://psychopharmacologyinstitute.com/publication/pharmacologic-management-of-bpd-recent-developments-interview-26942025-03-19never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-46-26932024-08-15never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-45-26922024-08-15never0.5https://psychopharmacologyinstitute.com/publication/pharmacotherapies-for-stimulant-use-disorder-interview-26912024-08-14never0.5https://psychopharmacologyinstitute.com/publication/december-2021-newsletter-early-treatment-with-fluvoxamine-among-patients-with-covid-19-assessment-and-management-of-first-episode-of-psychosis-and-the-clinical-guide-to-adult-adhd-26902021-11-30never0.5https://psychopharmacologyinstitute.com/publication/broad-spectrum-micronutrients-bsm-for-mental-health-context-for-considering-micronutrient-treatment-26892024-08-14never0.5https://psychopharmacologyinstitute.com/publication/managing-some-unique-nonhematologic-adverse-effects-of-clozapine-26882024-08-14never0.5https://psychopharmacologyinstitute.com/publication/november-2021-newsletter-national-emergency-in-youth-mental-health-medicinal-cannabis-and-the-psychiatric-patient-and-lithium-dosage-side-effects-and-how-to-persuade-patients-to-take-it-26872021-11-03never0.5https://psychopharmacologyinstitute.com/publication/october-2021-newsletter-six-month-paliperidone-palmitate-for-schizophrenia-the-psychopharmacology-algorithm-for-psychotic-depression-and-treatment-resistant-ocd-26862021-11-03never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-44-26852024-08-15never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-43-26842024-08-15never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-42-26832024-08-15never0.5https://psychopharmacologyinstitute.com/publication/september-2021-newsletter-prenatal-exposure-to-antipsychotics-understanding-the-use-of-psychotropic-drugs-in-lactation-and-the-clinical-guide-on-tobacco-use-disorder-26822021-11-03never0.5https://psychopharmacologyinstitute.com/publication/medicinal-cannabis-and-the-psychiatric-patient-clinical-harm-vs-novel-treatment-interview-26812024-08-14never0.5https://psychopharmacologyinstitute.com/publication/assessment-and-management-of-first-episode-of-psychosis-interview-26802024-08-14never0.5https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-algorithm-for-psychotic-depression-interview-26792024-08-14never0.5https://psychopharmacologyinstitute.com/publication/understanding-the-use-of-psychotropic-drugs-in-lactation-interview-26782024-08-14never0.5https://psychopharmacologyinstitute.com/publication/natural-medications-in-child-and-adolescent-psychiatry-26772024-08-14never0.5https://psychopharmacologyinstitute.com/publication/algorithm-for-the-pharmacotherapy-of-obsessive-compulsive-disorder-26762024-10-21never0.5https://psychopharmacologyinstitute.com/publication/atypical-psychopharmacologic-strategies-for-children-and-adolescents-26752024-08-14never0.5https://psychopharmacologyinstitute.com/publication/august-2021-newsletter-zuranolone-for-postpartum-depression-what-clinicians-need-to-know-about-alcohol-use-disorder-and-the-clinical-guide-to-sleep-issues-in-psychiatry-26712021-11-03never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-41-26702024-08-15never0.5https://psychopharmacologyinstitute.com/publication/psychotropic-drug-adherence-interview-26692024-08-14never0.5https://psychopharmacologyinstitute.com/publication/updates-on-geriatric-psychopharmacology-26682025-06-04never0.5https://psychopharmacologyinstitute.com/publication/july-2021-newsletter-fdas-approval-of-aducanumab-for-alzheimers-disease-psychotropic-drug-adherence-and-treating-perimenopausal-depression-26672021-11-03never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-40-26582024-08-15never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-39-26572024-08-15never0.5https://psychopharmacologyinstitute.com/publication/management-of-delirium-interview-26562024-08-14never0.5https://psychopharmacologyinstitute.com/publication/use-of-psychotropics-in-patients-with-hepatic-issues-interview-26552024-08-14never0.5https://psychopharmacologyinstitute.com/publication/psychosis-and-schizophrenia-in-children-and-adolescents-26542024-08-14never0.5https://psychopharmacologyinstitute.com/publication/june-2021-newsletter-lumateperone-for-bipolar-depression-management-of-delirium-and-laboratory-testing-in-the-practice-of-psychopharmacology-26532021-11-03never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-38-26452024-08-15never0.5https://psychopharmacologyinstitute.com/publication/parasomnias-triggered-by-antidepressant-medications-rem-sleep-behavior-disorder-and-restless-legs-syndrome-26442024-08-14never0.5https://psychopharmacologyinstitute.com/publication/may-2021-newsletter-vilaxozine-a-newly-approved-adhd-drug-for-children-use-of-psychotropics-in-patients-with-hepatic-issues-and-clinical-considerations-of-dopamine-and-depression-26432021-11-03never0.5https://psychopharmacologyinstitute.com/publication/antipsychotic-switching-intersection-of-art-and-science-26422024-08-14never0.5https://psychopharmacologyinstitute.com/publication/managing-explosive-behavior-in-children-and-adolescents-26412024-10-21never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-37-26402024-02-29never0.5https://psychopharmacologyinstitute.com/publication/april-2021-newsletter-the-abcs-of-successful-vaccinationsa-role-for-psychiatry-the-psychopharmacology-of-feeding-and-eating-disorders-and-clinical-essentials-of-drug-induced-movement-disorders-26382021-11-03never0.5https://psychopharmacologyinstitute.com/publication/march-2021-newsletter-covid-survivors-may-have-ptsd-evidence-based-treatment-of-major-depressive-episodes-in-later-life-and-an-algorithm-for-the-psychopharmacology-of-unipolar-nonpsychotic-depression-26362023-08-29never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-36-26352024-02-29never0.5https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-of-feeding-and-eating-disorders-interview-26342025-04-01never0.5https://psychopharmacologyinstitute.com/publication/pharmacologic-management-of-bpd-recent-developments-26332025-03-31never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-35-26322024-02-29never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-34-26312024-02-29never0.5https://psychopharmacologyinstitute.com/publication/management-of-behavioral-and-psychological-symptoms-of-dementia-26302025-03-31never0.5https://psychopharmacologyinstitute.com/publication/february-2021-newsletter-updated-guideline-for-the-treatment-of-patients-with-schizophrenia-obsessive-compulsive-and-related-disorders-and-bipolar-disorder-in-later-life-26292023-08-29never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-23-26272024-02-29never0.5https://psychopharmacologyinstitute.com/publication/ocd-in-children-and-adolescents-26262024-08-14never0.5https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-algorithm-for-psychotic-depression-26252024-08-14never0.5https://psychopharmacologyinstitute.com/publication/obsessive-compulsive-and-related-disorders-interview-26242025-06-23never0.5https://psychopharmacologyinstitute.com/publication/what-clinicians-need-to-know-about-alcohol-use-disorder-interview-26232025-06-23never0.5https://psychopharmacologyinstitute.com/publication/experimental-pharmacotherapies-for-stimulant-use-disorder-26222024-08-14never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-33-26212024-08-15never0.5https://psychopharmacologyinstitute.com/publication/premenstrual-mood-syndromes-interview-26202025-06-23never0.5https://psychopharmacologyinstitute.com/publication/top-10-drug-combinations-in-major-depressive-disorder-interview-with-dr-michael-thase-part-2-26192023-08-29never0.5https://psychopharmacologyinstitute.com/publication/top-10-drug-combinations-in-major-depressive-disorder-interview-with-dr-michael-thase-part-1-26182021-11-08never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-32-26172024-08-15never0.5https://psychopharmacologyinstitute.com/publication/the-clinical-guide-to-adult-adhd-interview-26162025-06-23never0.5https://psychopharmacologyinstitute.com/publication/understanding-the-use-of-psychotropic-drugs-in-lactation-26152024-08-14never0.5https://psychopharmacologyinstitute.com/publication/medicinal-cannabis-and-the-psychiatric-patient-clinical-harm-vs-novel-treatment-26142024-08-14never0.5https://psychopharmacologyinstitute.com/publication/reducing-suicidal-ideation-through-insomnia-treatment-a-randomized-clinical-trial-26132021-11-08never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-31-26122024-02-29never0.5https://psychopharmacologyinstitute.com/publication/assessment-and-management-of-first-episode-of-psychosis-26112024-08-14never0.5https://psychopharmacologyinstitute.com/publication/lithium-how-to-manage-dosage-and-side-effects-and-persuade-patients-to-take-it-interview-26102025-06-23never0.5https://psychopharmacologyinstitute.com/publication/the-clinical-guide-on-tobacco-use-disorder-interview-26092025-06-23never0.5https://psychopharmacologyinstitute.com/publication/treatment-resistant-obsessive-compulsive-disorder-interview-26082025-06-23never0.5https://psychopharmacologyinstitute.com/publication/the-clinicians-algorithm-to-managing-covid-19-related-delirium-26072021-11-08never0.5https://psychopharmacologyinstitute.com/publication/psychotropic-drug-adherence-26062024-02-29never0.5https://psychopharmacologyinstitute.com/publication/does-samidorphan-reduce-olanzapine-induced-weight-gain-26052021-11-08never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-30-26042024-02-29never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-29-26032024-02-29never0.5https://psychopharmacologyinstitute.com/publication/managing-depression-anxiety-and-psychosis-in-parkinsons-disease-26022021-11-08never0.5https://psychopharmacologyinstitute.com/publication/evidence-based-treatment-of-major-depressive-episodes-in-later-life-26012024-08-14never0.5https://psychopharmacologyinstitute.com/publication/management-of-psychiatric-disturbances-in-parkinsons-disease-and-other-hypokinetic-movement-disorders-26002021-11-08never0.5https://psychopharmacologyinstitute.com/publication/dopamine-and-depression-clinical-considerations-interview-25992025-06-23never0.5https://psychopharmacologyinstitute.com/publication/neurocovid-pharmacological-recommendations-for-delirium-associated-with-covid-19-interview-25982025-06-23never0.5https://psychopharmacologyinstitute.com/publication/june-2020-newsletter-discharges-during-covid-19-cardiac-side-effects-of-psychotropics-tobacco-use-disorder-and-more-25972023-08-29never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-28-25962024-08-15never0.5https://psychopharmacologyinstitute.com/publication/the-clinical-guide-to-sleep-issues-in-psychiatry-interview-25952025-06-23never0.5https://psychopharmacologyinstitute.com/publication/case-discussion-managing-agitation-in-autism-spectrum-disorder-25942021-11-08never0.5https://psychopharmacologyinstitute.com/publication/management-of-delirium-25932024-08-14never0.5https://psychopharmacologyinstitute.com/publication/may-2020-newsletter-telepsychiatry-and-covid-19-perinatal-psychopharmacology-sleep-issues-in-psychiatry-and-more-25922021-11-03never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-27-25912024-02-29never0.5https://psychopharmacologyinstitute.com/publication/blue-moods-and-hot-flashes-treating-perimenopausal-depression-interview-25902025-06-23never0.5https://psychopharmacologyinstitute.com/publication/pharmacotherapy-of-autism-spectrum-disorder-randomized-baart-clinical-trial-25882021-11-08never0.5https://psychopharmacologyinstitute.com/publication/use-of-psychotropics-in-patients-with-hepatic-issues-25822024-08-14never0.5https://psychopharmacologyinstitute.com/publication/gad-psychopharmacology-algorithm-interview-25812025-06-23never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-26-25802024-02-29never0.5https://psychopharmacologyinstitute.com/publication/antidepressant-safety-during-pregnancy-autism-iq-and-teratogenicity-25792021-11-08never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-25-25782024-02-29never0.5https://psychopharmacologyinstitute.com/publication/top-10-drug-combinations-in-mdd-interview-25772025-06-23never0.5https://psychopharmacologyinstitute.com/publication/obsessive-compulsive-and-related-disorders-25762024-08-14never0.5https://psychopharmacologyinstitute.com/publication/does-prenatal-stress-predispose-to-borderline-personality-disorder-25752021-11-08never0.5https://psychopharmacologyinstitute.com/publication/march-2020-newsletter-covid-19-tms-for-bipolar-depression-and-postpartum-mood-disorders-25742021-11-03never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-24-25732024-02-29never0.5https://psychopharmacologyinstitute.com/publication/clinical-pearls-in-perinatal-psychiatry-25712021-11-08never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-14-25702022-04-01never0.5https://psychopharmacologyinstitute.com/publication/what-do-you-know-about-cognitive-enhancers-in-depression-25672021-11-08never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-13-25662022-04-01never0.5https://psychopharmacologyinstitute.com/publication/pharmacotherapy-of-psychiatric-syndromes-in-parkinsons-disease-interview-25652025-06-23never0.5https://psychopharmacologyinstitute.com/publication/february-2020-newsletter-lumateperone-unipolar-depression-natural-medications-and-more-25642021-11-03never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-12-25632022-04-01never0.5https://psychopharmacologyinstitute.com/publication/psychiatric-pharmacogenomics-interview-25622025-06-23never0.5https://psychopharmacologyinstitute.com/publication/laboratory-testing-in-the-practice-of-psychopharmacology-interview-25602025-06-23never0.5https://psychopharmacologyinstitute.com/publication/clinical-management-of-bipolar-disorder-in-pregnancy-25592024-08-14never0.5https://psychopharmacologyinstitute.com/publication/can-lithium-prevent-dementia-25582021-11-08never0.5https://psychopharmacologyinstitute.com/publication/drug-induced-movement-disorders-the-clinical-essentials-25572024-08-14never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-11-25562022-04-01never0.5https://psychopharmacologyinstitute.com/publication/cardiac-side-effects-of-psychiatric-medications-interview-25552025-06-23never0.5https://psychopharmacologyinstitute.com/publication/psychopharm-in-2019-your-ultimate-guide-25502021-11-08never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-22-25492024-02-29never0.5https://psychopharmacologyinstitute.com/publication/bipolar-disorder-in-later-life-interview-25482025-06-23never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-10-25462022-04-01never0.5https://psychopharmacologyinstitute.com/publication/2019-in-review-new-drugs-indications-and-formulations-25432021-11-03never0.5https://psychopharmacologyinstitute.com/publication/clinical-storytime-with-dr-ken-gillman-25422021-11-08never0.5https://psychopharmacologyinstitute.com/publication/the-clinicians-guide-to-postpartum-mood-disorders-25412023-03-20never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-21-25402023-11-30never0.5https://psychopharmacologyinstitute.com/publication/use-of-ketamine-interview-25392025-06-23never0.5https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-of-feeding-and-eating-disorders-25382024-08-14never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-9-25372022-04-01never0.5https://psychopharmacologyinstitute.com/publication/do-antidepressants-increase-risk-of-dementia-25362021-11-08never0.5https://psychopharmacologyinstitute.com/publication/behind-the-scenes-meet-our-team-25352021-11-08never0.5https://psychopharmacologyinstitute.com/publication/an-algorithm-for-the-psychopharmacology-of-unipolar-nonpsychotic-depression-25342022-04-01never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-20-25332023-11-30never0.5https://psychopharmacologyinstitute.com/publication/new-antidepressants-a-quick-takes-episode-25312021-11-08never0.5https://psychopharmacologyinstitute.com/publication/perinatal-psychopharmacology-helping-patients-make-decisions-in-pregnancy-interview-25302025-06-23never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-8-25292022-04-01never0.5https://psychopharmacologyinstitute.com/publication/why-dont-we-prescribe-maois-25282021-11-08never0.5https://psychopharmacologyinstitute.com/publication/tms-in-psychiatry-a-practical-update-interview-25272025-06-23never0.5https://psychopharmacologyinstitute.com/publication/bipolar-disorder-in-later-life-25262022-04-01never0.5https://psychopharmacologyinstitute.com/publication/ketamine-for-suicidal-ideation-a-quick-take-episode-25252021-11-08never0.5https://psychopharmacologyinstitute.com/publication/treatment-strategies-for-catatonia-interview-25242025-06-23never0.5https://psychopharmacologyinstitute.com/publication/treatment-resistant-obsessive-compulsive-disorder-25232024-08-14never0.5https://psychopharmacologyinstitute.com/publication/drug-induced-movement-disorders-the-clinical-essentials-interview-25222025-06-23never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-7-25212022-04-01never0.5https://psychopharmacologyinstitute.com/publication/the-basic-guide-to-ketamine-and-esketamine-25202021-11-08never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-19-25192023-03-20never0.5https://psychopharmacologyinstitute.com/publication/an-algorithm-for-the-psychopharmacology-of-unipolar-nonpsychotic-depression-interview-25182025-06-23never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-18-25172023-03-20never0.5https://psychopharmacologyinstitute.com/publication/the-clinical-guide-to-sleep-issues-in-psychiatry-25162023-03-20never0.5https://psychopharmacologyinstitute.com/publication/your-psych-guide-to-pharmacogenetic-testing-25152021-11-08never0.5https://psychopharmacologyinstitute.com/publication/do-you-order-pharmacogenetic-testing-for-your-patients-25142021-11-08never0.5https://psychopharmacologyinstitute.com/publication/premenstrual-mood-syndromes-25132024-02-29never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-17-25122023-03-20never0.5https://psychopharmacologyinstitute.com/publication/doing-more-by-prescribing-less-top-10-pharmacodynamic-interactions-interview-25112025-06-23never0.5https://psychopharmacologyinstitute.com/publication/the-clinical-guide-to-adult-adhd-25102024-02-29never0.5https://psychopharmacologyinstitute.com/publication/transdermal-patches-in-psychiatry-interview-with-dr-leslie-citrome-25092021-11-08never0.5https://psychopharmacologyinstitute.com/publication/treatment-of-bipolar-disorder-in-children-and-adolescents-25072022-04-01never0.5https://psychopharmacologyinstitute.com/publication/clinical-guide-to-synthetic-opioids-and-bath-salts-25052021-11-08never0.5https://psychopharmacologyinstitute.com/publication/designer-drugs-can-you-handle-spice-25032021-11-08never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-16-25022023-03-20never0.5https://psychopharmacologyinstitute.com/publication/what-you-need-to-know-about-psychedelics-24982021-11-08never0.5https://psychopharmacologyinstitute.com/publication/the-magic-of-the-serotonin-receptors-24962021-11-08never0.5https://psychopharmacologyinstitute.com/publication/what-clinicians-need-to-know-about-alcohol-use-disorder-24942024-08-14never0.5https://psychopharmacologyinstitute.com/publication/blue-moods-and-hot-flashes-treating-perimenopausal-depression-24932024-02-29never0.5https://psychopharmacologyinstitute.com/publication/the-clinical-guide-on-tobacco-use-disorder-24922024-08-14never0.5https://psychopharmacologyinstitute.com/publication/introduction-to-the-bipolar-mania-and-hypomania-algorithm-24902023-11-30never0.5https://psychopharmacologyinstitute.com/publication/generalized-anxiety-disorder-what-if-you-cant-use-an-ssri-24892021-11-08never0.5https://psychopharmacologyinstitute.com/publication/approaching-a-case-of-generalized-anxiety-disorder-the-basics-24862023-08-30never0.5https://psychopharmacologyinstitute.com/publication/how-helpful-are-antipsychotic-plasma-levels-24842021-11-08never0.5https://psychopharmacologyinstitute.com/publication/how-to-prescribe-natural-medications-part-2-24822021-11-08never0.5https://psychopharmacologyinstitute.com/publication/how-to-prescribe-natural-medications-part-1-24802021-11-08never0.5https://psychopharmacologyinstitute.com/publication/how-to-manage-adverse-effects-of-clozapine-part-2-24782021-11-08never0.5https://psychopharmacologyinstitute.com/publication/how-to-manage-adverse-effects-of-clozapine-part-1-24762021-11-08never0.5https://psychopharmacologyinstitute.com/publication/do-ssris-increase-bleeding-risk-24742021-11-08never0.5https://psychopharmacologyinstitute.com/publication/your-guide-to-treating-ptsd-comorbidities-24722021-11-08never0.5https://psychopharmacologyinstitute.com/publication/pharmacotherapy-of-psychiatric-syndromes-in-parkinsons-disease-23532022-04-01never0.5https://psychopharmacologyinstitute.com/publication/psychiatric-pharmacogenomics-23522022-08-26never0.5https://psychopharmacologyinstitute.com/publication/cardiac-side-effects-of-psychiatric-medications-23512022-04-01never0.5https://psychopharmacologyinstitute.com/publication/ketamine-in-clinical-practice-state-of-the-art-usage-23502022-04-01never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-6-23302022-04-01never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-15-23292022-04-01never0.5https://psychopharmacologyinstitute.com/publication/treatment-of-bipolar-disorder-in-children-and-adolescents-interview-23242025-06-23never0.5https://psychopharmacologyinstitute.com/publication/modern-use-of-maois-interview-23232025-06-23never0.5https://psychopharmacologyinstitute.com/publication/introduction-to-the-bipolar-mania-and-hypomania-algorithm-interview-23222025-06-23never0.5https://psychopharmacologyinstitute.com/publication/laboratory-testing-in-the-practice-of-psychopharmacology-23152023-03-20never0.5https://psychopharmacologyinstitute.com/publication/doing-more-by-prescribing-less-top-10-pharmacodynamic-interactions-22912022-04-01never0.5https://psychopharmacologyinstitute.com/publication/modern-use-of-maois-22892023-03-20never0.5https://psychopharmacologyinstitute.com/publication/natural-medications-in-psychiatry-interview-22842025-06-23never0.5https://psychopharmacologyinstitute.com/publication/modern-use-of-antipsychotic-plasma-levels-interview-22832025-06-23never0.5https://psychopharmacologyinstitute.com/publication/ptsd-psychopharmacology-algorithm-interview-22822025-06-23never0.5https://psychopharmacologyinstitute.com/publication/managing-nonhematological-adverse-effects-of-clozapine-interview-22802025-06-23never0.5https://psychopharmacologyinstitute.com/publication/geriatric-psychopharmacology-update-interview-22792025-06-23never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-5-22782022-04-01never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-4-22772022-04-01never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-3-22752022-03-30never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-2-22742022-03-30never0.5https://psychopharmacologyinstitute.com/publication/quick-take-vol-1-22732022-03-30never0.5https://psychopharmacologyinstitute.com/publication/how-to-treat-ptsd-related-sleep-disturbances-22722021-11-08never0.5https://psychopharmacologyinstitute.com/publication/prescribing-psychotropics-in-the-medically-ill-22712021-11-08never0.5https://psychopharmacologyinstitute.com/publication/psychotropics-and-gastrointestinal-conditions-prescribe-with-the-gut-in-mind-22702021-11-08never0.5https://psychopharmacologyinstitute.com/publication/recommendations-for-treatment-resistant-depression-interview-22692025-06-23never0.5https://psychopharmacologyinstitute.com/publication/designer-drugs-a-practical-update-22682022-04-01never0.5https://psychopharmacologyinstitute.com/publication/clinical-pearls-in-geriatric-psychopharmacology-22672021-11-08never0.5https://psychopharmacologyinstitute.com/publication/treatment-resistant-depression-clinical-conundrum-22662021-11-08never0.5https://psychopharmacologyinstitute.com/publication/how-to-manage-an-agitated-patient-22642021-11-08never0.5https://psychopharmacologyinstitute.com/publication/when-to-discontinue-antipsychotics-reviewing-the-evidence-22612021-11-08never0.5https://psychopharmacologyinstitute.com/publication/are-drug-interaction-warnings-influenced-by-drug-company-promotion-an-interview-with-dr-jeffrey-mattes-22582021-11-08never0.5https://psychopharmacologyinstitute.com/publication/do-depression-efficacy-trials-apply-to-your-clinical-practice-an-interview-with-dr-mark-zimmerman-22542021-11-08never0.5https://psychopharmacologyinstitute.com/publication/psilocybin-for-treatment-resistant-depression-an-interview-with-dr-robin-carhart-harris-22522021-11-08never0.5https://psychopharmacologyinstitute.com/publication/psychopharmacology-highlights-from-the-2018-apa-annual-meeting-22492023-03-13never0.5https://psychopharmacologyinstitute.com/publication/2018-apa-alcohol-use-disorder-guideline-summary-of-recommendations-22382023-03-13never0.5https://psychopharmacologyinstitute.com/publication/2017-in-review-new-drugs-formulations-and-clinical-guidelines-22372023-03-13never0.5https://psychopharmacologyinstitute.com/publication/antipsychotics-news-cariprazine-risperidone-and-new-drug-applications-22332023-03-13never0.5https://psychopharmacologyinstitute.com/publication/comments-on-the-2017-vadod-practice-guideline-for-the-management-of-ptsd-22302023-03-13never0.5https://psychopharmacologyinstitute.com/publication/mirtazapine-essentials-moa-indications-adverse-effects-pharmacokinetics-and-dosing-22222023-03-13never0.5https://psychopharmacologyinstitute.com/publication/cannabis-and-mental-health-2017-report-of-the-national-academy-of-sciences-engineering-and-medicine-22182021-11-03never0.5https://psychopharmacologyinstitute.com/publication/sertraline-essentials-mechanism-of-action-indications-pharmacokinetics-and-dosing-22162023-03-13never0.5https://psychopharmacologyinstitute.com/publication/2016-in-review-a-psychopharmacology-update-for-clinicians-22142023-03-13never0.5https://psychopharmacologyinstitute.com/publication/antidepressant-discontinuation-syndrome-diagnosis-prevention-and-management-22132023-03-13never0.5https://psychopharmacologyinstitute.com/publication/lithiums-mechanism-of-action-an-illustrated-review-22122023-03-13never0.5https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-of-fluoxetine-mechanism-of-action-indications-pharmacokinetics-and-dosing-22102024-03-23never0.5https://psychopharmacologyinstitute.com/publication/bipolar-disorder-treatment-guidelines-a-2018-update-22062023-03-13never0.5https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-of-paroxetine-mechanism-of-action-indications-pharmacokinetics-and-dosing-22042024-03-22never0.5https://psychopharmacologyinstitute.com/publication/long-acting-injectable-antipsychotics-a-practical-guide-for-prescribers-22012023-03-13never0.5https://psychopharmacologyinstitute.com/publication/summary-of-newly-approved-antipsychotics-22002021-11-03never0.5https://psychopharmacologyinstitute.com/publication/methylphenidate-for-adhd-mechanism-of-action-and-formulations-21942023-03-13never0.5https://psychopharmacologyinstitute.com/publication/new-paliperidone-formulation-approved-invega-trinza-21922023-03-13never0.5https://psychopharmacologyinstitute.com/publication/pharmacotherapy-of-treatment-resistant-ocd-augmentation-strategies-21912023-03-13never0.5https://psychopharmacologyinstitute.com/publication/lisdexamfetamine-approved-for-binge-eating-disorder-21902023-03-13never0.5https://psychopharmacologyinstitute.com/publication/valproate-in-psychiatry-approved-indications-and-off-label-uses-21882024-03-20never0.5https://psychopharmacologyinstitute.com/publication/2014-in-review-new-guidelines-and-drug-approvals-21852022-05-19never0.5https://psychopharmacologyinstitute.com/publication/fda-warning-ziprasidone-associated-with-dress-syndrome-21842023-03-13never0.5https://psychopharmacologyinstitute.com/publication/opioid-receptors-21822023-03-13never0.5https://psychopharmacologyinstitute.com/publication/citalopram-and-escitalopram-a-summary-of-key-differences-and-similarities-21792024-10-25never0.5https://psychopharmacologyinstitute.com/publication/venlafaxine-and-desvenlafaxine-differences-and-similarities-21782023-03-13never0.5https://psychopharmacologyinstitute.com/publication/antidepressants-and-weight-change-an-evidence-based-tool-21762024-03-23never0.5https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-of-bupropion-an-illustrated-overview-21742023-03-13never0.5https://psychopharmacologyinstitute.com/publication/psychopharmacology-journals-and-resources-21712023-03-13never0.5https://psychopharmacologyinstitute.com/publication/adverse-effects-of-ssris-21692024-03-19never0.5https://psychopharmacologyinstitute.com/publication/ziprasidone-adverse-effects-21672024-03-23never0.5https://psychopharmacologyinstitute.com/publication/ziprasidone-geodon-pharmacokinetics-21662024-03-21never0.5https://psychopharmacologyinstitute.com/publication/mechanism-of-action-and-pharmacodynamics-of-ziprasidone-21652024-03-22never0.5https://psychopharmacologyinstitute.com/publication/ziprasidone-geodon-indications-fda-approved-uses-21642023-03-13never0.5https://psychopharmacologyinstitute.com/publication/olanzapine-interactions-21632024-03-21never0.5https://psychopharmacologyinstitute.com/publication/olanzapine-adverse-effects-21622024-03-23never0.5https://psychopharmacologyinstitute.com/publication/mechanism-of-action-and-pharmacodynamics-of-olanzapine-21612024-03-19never0.5https://psychopharmacologyinstitute.com/publication/olanzapine-indications-fda-approved-uses-21602024-03-22never0.5https://psychopharmacologyinstitute.com/publication/olanzapine-pharmacokinetics-21592024-03-20never0.5https://psychopharmacologyinstitute.com/publication/iloperidone-fanapt-indications-fda-approved-uses-21562023-03-13never0.5https://psychopharmacologyinstitute.com/publication/iloperidone-fanapt-drug-interactions-21552023-03-13never0.5https://psychopharmacologyinstitute.com/publication/iloperidone-fanapt-adverse-effects-and-warnings-21542023-03-13never0.5https://psychopharmacologyinstitute.com/publication/mechanism-of-action-and-pharmacodynamics-of-iloperidone-fanapt-21532023-03-13never0.5https://psychopharmacologyinstitute.com/publication/iloperidone-pharmacokinetics-21522023-03-13never0.5https://psychopharmacologyinstitute.com/publication/lurasidone-latuda-interactions-21502024-03-21never0.5https://psychopharmacologyinstitute.com/publication/lurasidone-indications-fda-approved-uses-21482023-03-13never0.5https://psychopharmacologyinstitute.com/publication/lurasidone-adverse-effects-21472023-03-13never0.5https://psychopharmacologyinstitute.com/publication/asenapine-indications-fda-approved-uses-21462023-03-13never0.5https://psychopharmacologyinstitute.com/publication/lurasidone-pharmacokinetics-21452024-03-23never0.5https://psychopharmacologyinstitute.com/publication/asenapine-interactions-21432023-03-13never0.5https://psychopharmacologyinstitute.com/publication/asenapine-adverse-effects-21422023-03-13never0.5https://psychopharmacologyinstitute.com/publication/mechanism-of-action-and-pharmacodynamics-of-asenapine-21412024-03-23never0.5https://psychopharmacologyinstitute.com/publication/asenapine-saphris-pharmacokinetics-21402024-03-23never0.5https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-ssris-21352023-03-13never0.5https://psychopharmacologyinstitute.com/publication/quetiapine-for-mania-21322024-03-21never0.5https://psychopharmacologyinstitute.com/publication/quetiapine-for-bipolar-depression-21312024-03-21never0.5https://psychopharmacologyinstitute.com/publication/quetiapine-for-depression-21302024-03-20never0.5https://psychopharmacologyinstitute.com/publication/aripiprazole-for-schizophrenia-21292024-03-22never0.5https://psychopharmacologyinstitute.com/publication/aripiprazole-for-depression-21282024-03-21never0.5https://psychopharmacologyinstitute.com/publication/aripiprazole-for-mania-21272024-03-20never0.5https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-risperidone-21262022-10-27never0.5https://psychopharmacologyinstitute.com/publication/pharmacokinetics-of-risperidone-clinical-summary-21252024-03-20never0.5https://psychopharmacologyinstitute.com/publication/risperidone-indications-fda-approved-and-off-label-uses-21242024-03-20never0.5https://psychopharmacologyinstitute.com/publication/5-ht1a-receptors-in-psychopharmacology-21232023-03-13never0.5https://psychopharmacologyinstitute.com/publication/aripiprazole-indications-fda-approved-and-off-label-uses-21202024-03-20never0.5https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-aripiprazole-21192023-03-13never0.5https://psychopharmacologyinstitute.com/publication/pharmacokinetics-of-aripiprazole-clinical-summary-21182024-03-21never0.5https://psychopharmacologyinstitute.com/publication/d2-receptors-in-psychopharmacology-21162023-10-12never0.5https://psychopharmacologyinstitute.com/publication/quetiapine-indications-fda-approved-and-off-label-uses-21122023-03-13never0.5https://psychopharmacologyinstitute.com/publication/quetiapine-pharmacokinetics-21112024-03-20never0.5https://psychopharmacologyinstitute.com/publication/first-generation-antipsychotics-an-introduction-21102024-03-19never0.5https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-21092023-03-13never0.5https://psychopharmacologyinstitute.com/publication/quetiapine-prescribing-information-21082023-03-13never0.5https://psychopharmacologyinstitute.com/publication/antipsychotic-agents-21072021-11-02never0.5https://psychopharmacologyinstitute.com/publication/the-four-dopamine-pathways-relevant-to-antipsychotics-pharmacology-20962023-03-13never0.5https://psychopharmacologyinstitute.com/publication/neurological-side-effects-of-antipsychotics-akathisia-dystonia-and-parkinsonism-20952023-03-13never0.5https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-antipsychotic-agents-20942023-08-29never0.5https://psychopharmacologyinstitute.com/publication/antipsychotics-for-schizophrenia-a-clinical-overview-20932023-03-13never0.5https://psychopharmacologyinstitute.com/publication/first-and-second-generation-antipsychotics-for-the-treatment-of-bipolar-disorder-20842024-03-22never0.5https://psychopharmacologyinstitute.com/publication/first-vs-second-generation-antipsychotics-20822023-02-16never0.5https://psychopharmacologyinstitute.com/publication/perinatal-psychopharmacology-helping-patients-make-decisions-in-pregnancy-20682022-04-01never0.5https://psychopharmacologyinstitute.com/publication/tms-in-psychiatry-a-practical-update-20672022-03-29never0.5https://psychopharmacologyinstitute.com/publication/natural-medications-in-psychiatry-20662022-04-01never0.5https://psychopharmacologyinstitute.com/publication/antipsychotic-blood-levels-20652022-04-01never0.5https://psychopharmacologyinstitute.com/publication/serotonin-update-psychedelics-and-5-ht-receptors-20642023-07-26never0.5https://psychopharmacologyinstitute.com/publication/gad-psychopharmacology-algorithm-20632022-03-29never0.5https://psychopharmacologyinstitute.com/publication/psychopharmacology-in-the-medically-ill-20622022-03-29never0.5https://psychopharmacologyinstitute.com/publication/managing-the-nonhematological-adverse-effects-of-clozapine-20612025-04-16never0.5https://psychopharmacologyinstitute.com/publication/schizophrenia-algorithm-lais-and-treatment-resistance-20602022-03-29never0.5https://psychopharmacologyinstitute.com/publication/lamotrigine-update-20592022-03-29never0.5https://psychopharmacologyinstitute.com/publication/emergency-psychopharmacology-20582025-04-16never0.5https://psychopharmacologyinstitute.com/publication/schizophrenia-psychopharmacology-algorithm-20572025-04-16never0.5https://psychopharmacologyinstitute.com/publication/geriatric-psychopharmacology-update-20562025-04-16never0.5https://psychopharmacologyinstitute.com/publication/treatment-resistant-depression-update-20552025-04-16never0.5https://psychopharmacologyinstitute.com/publication/cannabis-in-psychiatry-20542025-04-16never0.5https://psychopharmacologyinstitute.com/publication/antidepressant-basics-part-1-ssris-and-bupropion-20512025-04-16never0.5https://psychopharmacologyinstitute.com/publication/effective-assessment-and-management-of-behavioral-and-psychological-symptoms-of-dementia-20382025-04-16never0.5https://psychopharmacologyinstitute.com/publication/opioid-use-disorder-update-20372025-04-16never0.5https://psychopharmacologyinstitute.com/publication/ptsd-psychopharmacology-algorithm-20362025-04-16never0.5https://psychopharmacologyinstitute.com/section/prazosin-for-ptsd-related-nightmares-rationale-and-dosing-strategies-for-men-and-women-2036-39912025-04-16never0.5https://psychopharmacologyinstitute.com/section/trazodone-for-disturbed-sleep-initiation-in-ptsd-2036-39922025-04-16never0.5https://psychopharmacologyinstitute.com/section/the-neurobiology-of-behavioral-and-psychological-symptoms-of-dementia-an-illustrated-update-2038-40072025-04-16never0.5https://psychopharmacologyinstitute.com/section/the-mechanism-of-action-of-ssris-2051-40502025-04-16never0.5https://psychopharmacologyinstitute.com/section/the-psychopharmacology-of-fluoxetine-mechanism-of-action-indications-pharmacokinetics-and-dosing-2051-40512025-04-16never0.5https://psychopharmacologyinstitute.com/section/fluvoxamine-essentials-mechanism-of-action-indications-pharmacokinetics-and-dosing-2051-40522025-04-16never0.5https://psychopharmacologyinstitute.com/section/paroxetine-moa-indications-pharmacokinetics-and-dosing-2051-40532025-04-16never0.5https://psychopharmacologyinstitute.com/section/sertraline-moa-indications-pharmacokinetics-and-dosing-2051-40542025-04-16never0.5https://psychopharmacologyinstitute.com/section/citalopram-and-escitalopram-moa-indications-pharmacokinetics-and-dosing-2051-40552025-04-16never0.5https://psychopharmacologyinstitute.com/section/the-psychopharmacology-of-bupropion-an-illustrated-overview-2051-40562025-04-16never0.5https://psychopharmacologyinstitute.com/section/strategies-combination-and-augmentation-2055-40662025-04-16never0.5https://psychopharmacologyinstitute.com/section/inflammation-and-depression-use-of-anti-inflammatory-agents-and-the-role-of-inflammatory-markers-crp-2055-40732025-04-16never0.5https://psychopharmacologyinstitute.com/section/geriatric-psychopharmacology-how-pharmacokinetic-and-pharmacodynamic-changes-affect-prescribing-2056-40822025-04-16never0.5https://psychopharmacologyinstitute.com/section/managing-geriatric-bipolar-disorder-use-of-lithium-and-anticonvulsants-2056-40872025-04-16never0.5https://psychopharmacologyinstitute.com/section/antipsychotics-for-agitation-differences-between-tablets-orally-disintegrating-tablets-and-sublingual-formulations-2058-41082025-04-16never0.5https://psychopharmacologyinstitute.com/section/antipsychotic-induced-dystonia-diagnosis-and-management-2058-41122025-04-16never0.5https://psychopharmacologyinstitute.com/section/lamotrigine-is-not-slow-comments-about-its-efficacy-in-bipolar-depression-2059-41192023-08-30never0.5https://psychopharmacologyinstitute.com/section/lamotrigine-interactions-practical-recommendations-on-divalproex-carbamazepine-and-oral-contraceptives-use-2059-41202023-08-30never0.5https://psychopharmacologyinstitute.com/section/choosing-among-long-acting-injectable-antipsychotics-practical-aspects-2060-41222022-03-17never0.5https://psychopharmacologyinstitute.com/section/clozapine-augmentation-for-treatment-resistant-schizophrenia-what-does-the-evidence-say-2060-41242022-03-18never0.5https://psychopharmacologyinstitute.com/section/clozapine-induced-sialorrhea-why-is-it-important-and-how-should-you-manage-it-2061-41272025-04-16never0.5https://psychopharmacologyinstitute.com/section/managing-clozapine-induced-constipation-practical-advice-2061-41282025-04-16never0.5https://psychopharmacologyinstitute.com/section/ssris-and-bleeding-risk-what-does-the-evidence-say-2062-41402022-03-17never0.5https://psychopharmacologyinstitute.com/section/the-use-of-psychotropics-in-irritable-bowel-syndrome-and-bariatric-surgery-2062-41412022-03-17never0.5https://psychopharmacologyinstitute.com/section/gad-pharmacotherapy-addressing-comorbidities-and-special-populations-2063-41462022-03-17never0.5https://psychopharmacologyinstitute.com/section/gad-pharmacotherapy-augmenting-vs-switching-in-partial-responders-2063-41542023-08-29never0.5https://psychopharmacologyinstitute.com/section/the-role-of-serotonin-5-ht-in-impulsivityaggression-anxietystress-and-cognition-2064-41602023-07-26never0.5https://psychopharmacologyinstitute.com/section/the-use-of-mdma-for-ptsd-2064-41632022-03-17never0.5https://psychopharmacologyinstitute.com/section/antipsychotic-plasma-levels-and-adherence-2065-41692022-03-18never0.5https://psychopharmacologyinstitute.com/section/how-to-load-haloperidol-decanoate-2065-41722022-03-17never0.5https://psychopharmacologyinstitute.com/section/st-johns-wort-for-depression-a-clinical-summary-2066-41802022-03-17never0.5https://psychopharmacologyinstitute.com/section/s-adenosylmethionine-same-for-depression-what-does-the-evidence-say-2066-41812023-08-28never0.5https://psychopharmacologyinstitute.com/section/efficacy-of-tms-for-depression-results-from-clinical-trials-2067-41932022-03-17never0.5https://psychopharmacologyinstitute.com/section/tms-safety-results-from-clinical-trials-2067-41952022-03-17never0.5https://psychopharmacologyinstitute.com/section/reviewing-the-literature-antidepressants-and-teratogenicity-2068-42042022-03-18never0.5https://psychopharmacologyinstitute.com/section/reviewing-the-literature-ssris-in-pregnancy-and-association-with-autism-2068-42062022-03-18never0.5https://psychopharmacologyinstitute.com/section/are-psychostimulants-teratogenic-2273-43972020-09-07never0.5https://psychopharmacologyinstitute.com/section/liraglutide-for-weight-loss-in-patients-taking-olanzapine-or-clozapine-2273-43992020-09-07never0.5https://psychopharmacologyinstitute.com/section/stimulants-cardiovascular-effects-in-children-and-adolescents-2274-44002020-09-07never0.5https://psychopharmacologyinstitute.com/section/pimavanserin-for-alzheimers-2274-44012020-09-07never0.5https://psychopharmacologyinstitute.com/section/canmat-isbd-guidelines-for-acute-mania-2274-44032020-09-07never0.5https://psychopharmacologyinstitute.com/section/canmat-isbd-guidelines-for-bipolar-depression-2274-44042020-09-07never0.5https://psychopharmacologyinstitute.com/section/lithium-in-pregnancy-2275-44052020-09-07never0.5https://psychopharmacologyinstitute.com/section/alzheimers-apathy-2275-44062020-09-07never0.5https://psychopharmacologyinstitute.com/section/depression-in-schizophrenia-2277-44142020-09-07never0.5https://psychopharmacologyinstitute.com/section/are-ache-inhibitors-effective-2277-44152020-09-07never0.5https://psychopharmacologyinstitute.com/section/unipolar-depression-guidelines-a-comparison-2278-44182020-09-07never0.5https://psychopharmacologyinstitute.com/section/new-antidepressants-2278-44192020-09-07never0.5https://psychopharmacologyinstitute.com/section/depression-and-crp-2278-44202020-09-07never0.5https://psychopharmacologyinstitute.com/section/deprescribing-in-psychiatry-2330-44222020-09-07never0.5https://psychopharmacologyinstitute.com/section/thyroid-augmentation-for-major-depression-2330-44252020-09-07never0.5https://psychopharmacologyinstitute.com/section/efficacy-of-ketamine-in-depression-a-rapid-acting-antidepressant-2350-45262022-03-17never0.5https://psychopharmacologyinstitute.com/section/the-safety-and-tolerability-of-ketamine-concerns-and-questions-2350-45272022-03-17never0.5https://psychopharmacologyinstitute.com/section/how-should-i-use-antidepressants-in-patients-at-risk-for-qtc-prolongation-2351-45362023-08-28never0.5https://psychopharmacologyinstitute.com/section/cardiac-effects-of-antipsychotics-qtc-prolongation-2351-45382022-03-17never0.5https://psychopharmacologyinstitute.com/section/pharmacogenomics-in-psychiatry-antidepressant-metabolism-2352-45482022-03-17never0.5https://psychopharmacologyinstitute.com/section/pharmacogenomics-in-clinical-practice-recommendations-and-communicating-with-patients-2352-45522022-03-17never0.5https://psychopharmacologyinstitute.com/section/depression-in-parkinsons-disease-2353-45572022-03-17never0.5https://psychopharmacologyinstitute.com/section/psychosis-in-pd-management-strategies-2353-45602022-03-17never0.5https://psychopharmacologyinstitute.com/section/co-occurring-conditions-agitation-medical-comorbidities-and-anxiety-disorders-node-1-2490-46892022-03-17never0.5https://psychopharmacologyinstitute.com/section/management-of-mania-with-mixed-features-nodes-2a-2b-and-2c-2490-46912023-08-29never0.5https://psychopharmacologyinstitute.com/section/dietary-restriction-what-to-tell-patients-about-tyramine-2289-47132022-03-17never0.5https://psychopharmacologyinstitute.com/section/how-to-initiate-maoi-therapy-steps-to-follow-2289-47162022-03-17never0.5https://psychopharmacologyinstitute.com/section/childhood-and-adolescent-bipolar-depression-therapeutic-challenges-and-recommendations-2507-47202022-03-17never0.5https://psychopharmacologyinstitute.com/section/childhood-and-adolescent-bipolar-mania-clinical-pearls-on-using-lithium-2507-47222022-03-17never0.5https://psychopharmacologyinstitute.com/section/amphetamine-and-alprazolam-performance-heaven-or-hell-2291-47352022-03-17never0.5https://psychopharmacologyinstitute.com/section/venlafaxine-nightmares-and-prazosin-alpha-adrenoceptors-2291-47372022-03-17never0.5https://psychopharmacologyinstitute.com/section/ketamine-mechanism-2521-47402020-09-07never0.5https://psychopharmacologyinstitute.com/section/anticholinergic-reductions-2521-47412020-09-07never0.5https://psychopharmacologyinstitute.com/section/using-lithium-in-older-age-bipolar-disorder-2526-47492022-03-17never0.5https://psychopharmacologyinstitute.com/section/tremulous-with-lithium-the-case-of-marie-2526-47522022-03-17never0.5https://psychopharmacologyinstitute.com/section/navigating-treatment-maintenance-and-adherence-in-older-age-bipolar-disorder-2526-47552022-03-17never0.5https://psychopharmacologyinstitute.com/section/antipsychotic-drug-use-and-pneumonia-systematic-review-and-meta-analysis-2529-47582023-08-29never0.5https://psychopharmacologyinstitute.com/section/benzodiazepine-practicalities-2529-47602020-09-07never0.5https://psychopharmacologyinstitute.com/section/considering-medical-comorbidity-and-special-groups-in-mdd-treatment-2534-47652022-03-17never0.5https://psychopharmacologyinstitute.com/section/major-depressive-disorder-with-mixed-features-and-anxious-distress-special-considerations-2534-47662022-03-17never0.5https://psychopharmacologyinstitute.com/section/antidepressant-switching-after-the-first-failed-trial-in-major-depressive-disorder-node-4b-part-1-2534-47712023-08-29never0.5https://psychopharmacologyinstitute.com/section/pharmacologic-management-of-dementia-with-lewy-bodies-2537-47772020-09-07never0.5https://psychopharmacologyinstitute.com/section/cariprazine-treatment-of-bipolar-depression-a-randomized-double-blind-placebo-controlled-phase-3-study-2537-47782020-09-07never0.5https://psychopharmacologyinstitute.com/section/postpartum-depression-pharmacotherapy-antidepressants-and-brexanolone-2541-47852022-03-17never0.5https://psychopharmacologyinstitute.com/section/postpartum-psychosis-clinical-considerations-2541-47892022-03-17never0.5https://psychopharmacologyinstitute.com/section/treatment-strategies-for-postpartum-bipolar-disorder-and-psychosis-2541-47902022-03-17never0.5https://psychopharmacologyinstitute.com/section/efficacy-and-safety-of-intranasal-esketamine-adjunctive-to-oral-antidepressant-therapy-in-treatment-resistant-depression-2546-47932020-09-07never0.5https://psychopharmacologyinstitute.com/section/cannabidiol-for-the-reduction-of-cue-induced-craving-and-anxiety-in-drug-abstinent-individuals-with-heroin-use-disorder-a-double-blind-randomized-placebo-controlled-trial-2546-47962020-09-07never0.5https://psychopharmacologyinstitute.com/section/treatment-recommendations-for-tardive-dyskinesia-2556-47992020-09-07never0.5https://psychopharmacologyinstitute.com/section/efficacy-and-safety-of-deep-tms-for-ocd-2556-48022020-09-07never0.5https://psychopharmacologyinstitute.com/section/akathisia-how-to-diagnose-and-manage-2557-48042022-03-17never0.5https://psychopharmacologyinstitute.com/section/clinical-pointers-on-managing-extrapyramidal-symptoms-2557-48082022-03-14never0.5https://psychopharmacologyinstitute.com/section/treating-tardive-dyskinesia-a-clinical-conundrum-and-new-approaches-2557-48102022-03-17never0.5https://psychopharmacologyinstitute.com/section/gary-c-antipsychotic-induced-weight-gain-hyperlipidemia-and-metabolic-syndrome-2315-48132022-03-17never0.5https://psychopharmacologyinstitute.com/section/interpreting-liver-function-tests-2315-48152022-03-17never0.5https://psychopharmacologyinstitute.com/section/ecg-changes-with-psychotropic-treatment-2315-48192022-03-17never0.5https://psychopharmacologyinstitute.com/section/do-antidepressants-increase-the-risk-of-dementia-2563-48222020-09-07never0.5https://psychopharmacologyinstitute.com/section/pharmacotherapy-of-autism-spectrum-disorder-results-from-the-randomized-baart-clinical-trial-2563-48242023-08-30never0.5https://psychopharmacologyinstitute.com/section/a-single-ketamine-infusion-combined-with-mindfulness-based-behavioral-modification-to-treat-cocaine-dependence-a-randomized-clinical-trial-2566-48262020-09-07never0.5https://psychopharmacologyinstitute.com/section/comparative-efficacy-and-tolerability-of-32-oral-antipsychotics-for-the-acute-treatment-of-adults-with-multi-episode-schizophrenia-a-systematic-review-and-network-meta-analysis-2566-48292020-09-07never0.5https://psychopharmacologyinstitute.com/section/treatment-of-psychiatric-disturbances-in-hypokinetic-movement-disorders-2570-48392020-09-07never0.5https://psychopharmacologyinstitute.com/section/reducing-suicidal-ideation-through-insomnia-treatment-a-randomized-clinical-trial-2570-48402020-09-07never0.5https://psychopharmacologyinstitute.com/section/assessing-perimenopausal-depression-in-clinical-practice-2493-48442022-03-17never0.5https://psychopharmacologyinstitute.com/section/treatment-of-perimenopausal-depression-2493-48452022-03-17never0.5https://psychopharmacologyinstitute.com/section/guidelines-risks-and-benefits-of-hormone-therapy-2493-48472022-03-17never0.5https://psychopharmacologyinstitute.com/section/watching-out-for-tobaccodrug-interactions-pharmacokinetics-pharmacodynamics-and-deinduction-2492-48702022-03-17never0.5https://psychopharmacologyinstitute.com/section/psychosocial-interventions-for-tobacco-use-disorder-focus-on-motivational-interviewing-2492-48732022-03-17never0.5https://psychopharmacologyinstitute.com/section/using-e-cigarettes-what-clinicians-must-know-2492-48782022-03-17never0.5https://psychopharmacologyinstitute.com/section/benzodiazepine-use-during-pregnancy-alone-or-in-combination-with-an-antidepressant-and-congenital-malformations-systematic-review-and-meta-analysis-2329-48822020-09-08never0.5https://psychopharmacologyinstitute.com/section/the-potential-procognitive-effects-of-modafinil-in-major-depressive-disordera-systematic-review-2329-48832020-09-17never0.5https://psychopharmacologyinstitute.com/section/adequate-treatment-trials-in-ocd-fda-approvals-and-maximal-dosing-2523-48872022-03-17never0.5https://psychopharmacologyinstitute.com/section/second-generation-antipsychotics-and-other-augmentation-agents-in-treatment-resistant-ocd-2523-48912023-08-29never0.5https://psychopharmacologyinstitute.com/section/somatic-therapies-in-treatment-resistant-ocd-tms-and-dbs-2523-48922022-03-17never0.5https://psychopharmacologyinstitute.com/section/evaluating-the-efficacy-and-safety-of-antidepressants-in-patients-with-bipolar-disorder-2502-48952023-08-30never0.5https://psychopharmacologyinstitute.com/section/efficacy-and-safety-of-transcranial-direct-current-stimulation-for-treating-negative-symptoms-in-schizophrenia-2502-48982023-03-08never0.5https://psychopharmacologyinstitute.com/section/omega-3-and-polyunsaturated-fat-for-prevention-of-depression-and-anxiety-symptoms-meta-analyses-of-randomized-trials-2512-49022023-03-08never0.5https://psychopharmacologyinstitute.com/section/long-acting-injections-in-schizophrenia-a-3-year-update-on-randomized-controlled-trials-published-january-2016march-2019-2512-49032023-03-08never0.5https://psychopharmacologyinstitute.com/section/evidence-for-stress-like-alterations-in-the-hpa-axis-in-women-taking-oral-contraceptives-2517-49132023-03-08never0.5https://psychopharmacologyinstitute.com/section/a-network-meta-analysis-of-the-effects-of-psychotherapies-pharmacotherapies-and-their-combination-in-the-treatment-of-adult-depression-2517-49172023-03-08never0.5https://psychopharmacologyinstitute.com/section/assessment-of-adult-adhd-clinical-interview-and-rating-scales-2510-49212022-03-17never0.5https://psychopharmacologyinstitute.com/section/psychostimulants-for-adult-adhd-formulations-prescribing-tips-adverse-effects-and-monitoring-2510-49232022-03-17never0.5https://psychopharmacologyinstitute.com/section/nonstimulant-treatments-for-adult-adhd-atomoxetine-bupropion-alpha-agonists-and-others-2510-49252023-08-29never0.5https://psychopharmacologyinstitute.com/section/clozapine-treatment-and-risk-of-covid-19-2519-49302020-12-17never0.5https://psychopharmacologyinstitute.com/section/how-mental-health-care-should-change-as-a-consequence-of-the-covid-19-pandemic-2519-49322020-12-30never0.5https://psychopharmacologyinstitute.com/section/clinical-assessment-and-diagnosis-of-premenstrual-mood-syndromes-and-prospective-rating-scales-2513-49352022-03-17never0.5https://psychopharmacologyinstitute.com/section/psychopharmacology-for-pms-and-pmdd-luteal-phase-dosing-and-choosing-among-ssris-2513-49382022-03-17never0.5https://psychopharmacologyinstitute.com/section/hormonal-treatments-for-premenstrual-syndromes-oral-contraceptives-gnrh-agonists-and-oophorectomy-2513-49402022-03-17never0.5https://psychopharmacologyinstitute.com/section/case-vignette-discussion-diagnosing-and-treating-mary-c-2513-49412022-03-17never0.5https://psychopharmacologyinstitute.com/section/prescribing-lithium-during-pregnancy-pharmacokinetics-dosing-and-monitoring-2559-49482022-03-17never0.5https://psychopharmacologyinstitute.com/section/first-and-second-generation-antipsychotics-for-bipolar-disorder-during-pregnancy-2559-49492022-03-17never0.5https://psychopharmacologyinstitute.com/section/prescribing-antiepileptic-drugs-for-bipolar-disorder-during-pregnancy-valproate-carbamazepine-and-lamotrigine-2559-49502023-08-30never0.5https://psychopharmacologyinstitute.com/section/bipolar-emergencies-in-pregnancy-suicidality-and-mania-2559-49512022-03-17never0.5https://psychopharmacologyinstitute.com/section/comparative-effects-of-18-antipsychotics-on-metabolic-function-in-patients-with-schizophrenia-predictors-of-metabolic-dysregulation-and-association-with-psychopathology-a-systematic-review-and-network-meta-analysis-2540-49532023-08-30never0.5https://psychopharmacologyinstitute.com/section/cardiac-abnormalities-identified-with-echocardiography-in-anorexia-nervosa-systematic-review-and-meta-analysis-2540-49562021-02-11never0.5https://psychopharmacologyinstitute.com/section/hoarding-disorder-dsm-5-criteria-clinical-features-epidemiology-and-comorbidities-2576-49592022-03-17never0.5https://psychopharmacologyinstitute.com/section/body-dysmorphic-disorder-dsm-5-criteria-and-clinical-features-2576-49612022-03-17never0.5https://psychopharmacologyinstitute.com/section/body-dysmorphic-disorder-medications-cbt-and-exposure-response-prevention-therapy-2576-49622022-03-17never0.5https://psychopharmacologyinstitute.com/section/pharmacologic-treatment-of-hair-pulling-and-skin-picking-disorders-ssris-n-acetylcysteine-and-riluzole-2576-49642022-03-17never0.5https://psychopharmacologyinstitute.com/section/pharmacotherapy-for-borderline-personality-disorder-an-update-of-published-unpublished-and-ongoing-studies-2549-49672023-08-29never0.5https://psychopharmacologyinstitute.com/section/effectiveness-of-sequential-psychological-and-medication-therapies-for-insomnia-disorder-a-randomized-clinical-trial-2549-49712021-03-09never0.5https://psychopharmacologyinstitute.com/section/evidence-based-prevention-of-alzheimers-disease-systematic-review-and-meta-analysis-of-243-observational-prospective-studies-and-153-randomised-controlled-trials-2627-49722021-06-11never0.5https://psychopharmacologyinstitute.com/section/the-neuroleptic-malignant-syndromea-systematic-case-series-analysis-focusing-on-therapy-regimes-and-outcome-2627-49762021-05-11never0.5https://psychopharmacologyinstitute.com/section/remission-functional-recovery-and-prevention-of-relapse-and-recurrence-of-later-life-depression-2601-49802022-03-17never0.5https://psychopharmacologyinstitute.com/section/algorithm-for-later-life-depression-treatment-antidepressants-and-psychotherapy-2601-49812022-03-17never0.5https://psychopharmacologyinstitute.com/section/long-term-treatment-in-later-life-depression-maintenance-adverse-effects-and-combination-of-antidepressants-and-donepezil-2601-49832022-03-17never0.5https://psychopharmacologyinstitute.com/section/bereavement-and-terminal-illness-in-later-life-depression-complicated-grief-and-palliative-and-supportive-care-2601-49862022-03-17never0.5https://psychopharmacologyinstitute.com/section/impact-of-smoking-behavior-on-clozapine-blood-levelsa-systematic-review-and-meta-analysis-2573-49892021-04-13never0.5https://psychopharmacologyinstitute.com/section/in-search-of-a-dose-response-relationship-in-ssrisa-systematic-review-meta-analysis-and-network-meta-analysis-2573-49922023-08-28never0.5https://psychopharmacologyinstitute.com/section/food-avoidance-diagnosis-and-treatment-of-avoidantrestrictive-food-intake-disorder-arfid-2538-49942023-08-29never0.5https://psychopharmacologyinstitute.com/section/never-too-thin-anorexia-nervosa-an-diagnosis-and-overview-of-pharmacological-treatment-2538-49952022-03-17never0.5https://psychopharmacologyinstitute.com/section/bulimia-nervosa-bn-diagnosis-and-treatment-overview-2538-49992022-03-17never0.5https://psychopharmacologyinstitute.com/section/binge-eating-disorder-bed-diagnosis-and-treatment-overview-2538-50012022-03-17never0.5https://psychopharmacologyinstitute.com/section/diagnosis-and-impact-on-drug-metabolism-of-nonalcoholic-fatty-liver-disease-steatosis-and-nonalcoholic-steatohepatitis-2582-50072022-03-17never0.5https://psychopharmacologyinstitute.com/section/rating-scales-for-hepatic-dysfunction-child-pugh-2582-50082022-03-17never0.5https://psychopharmacologyinstitute.com/section/the-importance-of-child-pugh-classification-for-staging-hepatic-impairment-2582-50092022-03-17never0.5https://psychopharmacologyinstitute.com/section/valproatedivalproex-metabolism-kinetics-and-warnings-2582-50102022-03-17never0.5https://psychopharmacologyinstitute.com/section/emerging-complementary-and-integrative-therapies-for-geriatric-mental-health-2578-50162021-05-25never0.5https://psychopharmacologyinstitute.com/section/new-somatic-treatments-for-child-and-adolescent-depression-part-1-2578-50172023-03-09never0.5https://psychopharmacologyinstitute.com/section/delirium-assessment-consequences-and-sequelae-2593-50202022-03-17never0.5https://psychopharmacologyinstitute.com/section/management-of-delirium-nonpharmacologic-strategies-2593-50232022-03-14never0.5https://psychopharmacologyinstitute.com/section/haloperidol-chlorpromazine-and-atypical-antipsychotics-for-managing-delirium-2593-50242022-03-17never0.5https://psychopharmacologyinstitute.com/section/special-considerations-in-delirium-catatonia-and-covid-19-2593-50272022-03-17never0.5https://psychopharmacologyinstitute.com/section/effects-of-psilocybin-assisted-therapy-on-major-depressive-disorder-a-randomized-clinical-trial-2580-50312021-05-27never0.5https://psychopharmacologyinstitute.com/section/citalopram-for-acute-and-preventive-efficacy-in-bipolar-depression-cape-bd-a-randomized-double-blind-placebo-controlled-trial-2580-50332023-08-28never0.5https://psychopharmacologyinstitute.com/section/assessing-adherence-self-report-rating-scales-medication-refills-automated-pill-taking-frequency-monitoring-medication-routines-and-duration-of-assessments-2606-50382022-03-17never0.5https://psychopharmacologyinstitute.com/section/nonadherence-adverse-drug-reactions-measuring-perceived-side-effects-with-fibser-and-communication-about-side-effects-2606-50392022-03-17never0.5https://psychopharmacologyinstitute.com/section/improving-psychotropic-drug-adherence-targeting-reasons-for-nonadherence-and-the-3-tiered-approach-to-enhancing-adherence-2606-50402022-03-17never0.5https://psychopharmacologyinstitute.com/section/technology-facilitated-adherence-enhancement-and-family-involvement-2606-50412022-03-17never0.5https://psychopharmacologyinstitute.com/section/drug-induced-hyperthermic-syndromes-in-psychiatry-2591-50452023-03-09never0.5https://psychopharmacologyinstitute.com/section/postmarketing-safety-concerns-with-esketamine-a-disproportionality-analysis-of-spontaneous-reports-submitted-to-the-fda-adverse-event-reporting-system-2591-50462023-08-29never0.5https://psychopharmacologyinstitute.com/section/treatment-outcomes-of-electroconvulsive-therapy-for-depressed-patients-with-and-without-borderline-personality-disorder-a-retrospective-cohort-study-2596-50502021-09-07never0.5https://psychopharmacologyinstitute.com/section/increased-prevalence-of-subclinical-hypothyroidism-and-thyroid-autoimmunity-in-depressed-adolescents-results-from-a-clinical-cross-sectional-study-in-comparison-to-the-general-pediatric-population-2596-50542023-03-13never0.5https://psychopharmacologyinstitute.com/section/consequences-of-alcohol-use-disorder-withdrawal-2494-50572022-03-17never0.5https://psychopharmacologyinstitute.com/section/clinical-principles-on-managing-alcohol-use-disorder-2494-50592022-03-17never0.5https://psychopharmacologyinstitute.com/section/pharmacology-in-alcohol-use-disorder-naltrexone-acamprosate-and-disulfiram-2494-50602022-03-17never0.5https://psychopharmacologyinstitute.com/section/psychiatric-comorbidities-with-alcohol-use-disorder-prevalence-and-management-2494-50622022-03-17never0.5https://psychopharmacologyinstitute.com/section/a-method-for-tapering-antipsychotic-treatment-that-may-minimize-the-risk-of-relapse-2603-50642023-03-13never0.5https://psychopharmacologyinstitute.com/section/marine-omega-3-fatty-acid-supplementation-for-borderline-personality-disorder-a-meta-analysis-2603-50652021-09-07never0.5https://psychopharmacologyinstitute.com/section/medications-during-breastfeeding-guidelines-and-labels-2615-50712023-10-25never0.5https://psychopharmacologyinstitute.com/section/drug-use-in-breastfeeding-and-adverse-effects-2615-50732022-03-17never0.5https://psychopharmacologyinstitute.com/section/antidepressants-during-breastfeeding-2615-50742022-03-17never0.5https://psychopharmacologyinstitute.com/section/antipsychotics-during-breastfeeding-2615-50752022-03-17never0.5https://psychopharmacologyinstitute.com/section/fluvoxamine-vs-placebo-and-clinical-deterioration-in-outpatients-with-symptomatic-covid-19-2604-50822023-03-13never0.5https://psychopharmacologyinstitute.com/section/comparison-of-the-metabolic-characteristics-of-newer-second-generation-antipsychotics-2604-50832023-08-29never0.5https://psychopharmacologyinstitute.com/section/node-1-ect-for-severely-ill-patients-2625-50852022-03-17never0.5https://psychopharmacologyinstitute.com/section/node-2c-combination-therapy-snris-antipsychotics-2625-50882022-03-17never0.5https://psychopharmacologyinstitute.com/section/node-2-choosing-an-antipsychotic-for-psychotic-depression-2625-50892022-03-17never0.5https://psychopharmacologyinstitute.com/section/node-5-lithium-augmentation-2625-50912022-03-17never0.5https://psychopharmacologyinstitute.com/section/six-month-neurological-and-psychiatric-outcomes-in-236379-survivors-of-covid-19-a-retrospective-cohort-study-using-electronic-health-records-2612-50972024-01-11never0.5https://psychopharmacologyinstitute.com/section/agitation-and-dementia-prevention-and-treatment-strategies-in-acute-and-chronic-conditions-2612-50992024-01-11never0.5https://psychopharmacologyinstitute.com/section/does-cannabis-use-cause-psychiatric-disorders-2614-51022022-03-17never0.5https://psychopharmacologyinstitute.com/section/cannabis-and-cognition-2614-51032022-03-17never0.5https://psychopharmacologyinstitute.com/section/understanding-the-evidence-for-cbd-2614-51062022-03-17never0.5https://psychopharmacologyinstitute.com/section/cannabinoids-and-risks-for-patients-2614-51072022-03-17never0.5https://psychopharmacologyinstitute.com/section/management-of-first-episodes-antipsychotics-2611-51122022-03-17never0.5https://psychopharmacologyinstitute.com/section/psychopharmacology-for-people-with-treatment-resistant-early-psychosis-2611-51142022-03-17never0.5https://psychopharmacologyinstitute.com/section/health-concerns-for-first-episode-patients-2611-51152022-03-17never0.5https://psychopharmacologyinstitute.com/section/long-term-treatment-of-fep-2611-51172022-03-17never0.5https://psychopharmacologyinstitute.com/section/clozapine-induced-myocarditis-electronic-health-register-analysis-of-incidence-timing-clinical-markers-and-diagnostic-accuracy-2617-51192022-02-04never0.5https://psychopharmacologyinstitute.com/section/suicidality-and-self-injury-with-selective-serotonin-reuptake-inhibitors-in-youth-occurrence-predictors-and-timing-2617-51222023-03-13never0.5https://psychopharmacologyinstitute.com/section/stimulants-use-course-assessment-and-diagnosis-2622-51262022-03-17never0.5https://psychopharmacologyinstitute.com/section/stimulant-replacement-therapies-for-methamphetamine-and-amphetamine-use-disorder-2622-51282022-03-14never0.5https://psychopharmacologyinstitute.com/section/antidepressants-and-naltrexone-for-methamphetamine-use-disorder-2622-51292022-03-17never0.5https://psychopharmacologyinstitute.com/section/topiramate-and-methylphenidate-for-cocaine-use-disorder-and-its-comorbidities-2622-51312022-03-17never0.5https://psychopharmacologyinstitute.com/section/effects-on-suicidal-risk-comparison-of-clozapine-to-other-newer-medicines-indicated-to-treat-schizophrenia-or-bipolar-disorder-2621-51342023-08-30never0.5https://psychopharmacologyinstitute.com/section/prospects-for-new-drugs-to-treat-binge-eating-disorder-insights-from-psychopathology-and-neuropharmacology-2621-51382023-03-13never0.5https://psychopharmacologyinstitute.com/section/antipsychotics-for-bpd-2633-51402022-03-14never0.5https://psychopharmacologyinstitute.com/section/mood-stabilizers-for-bpd-lamotrigine-and-lithium-2633-51412022-03-14never0.5https://psychopharmacologyinstitute.com/section/omega-3-fatty-acids-methylphenidate-clonidine-doxazosin-memantine-and-oxytocin-for-bpd-2633-51432022-03-14never0.5https://psychopharmacologyinstitute.com/section/good-psychiatric-management-for-bpd-2633-51462022-03-14never0.5https://psychopharmacologyinstitute.com/section/the-effects-of-antipsychotic-treatment-on-the-brain-of-patients-with-first-episode-schizophrenia-a-selective-review-of-longitudinal-mri-studies-2631-51502023-08-30never0.5https://psychopharmacologyinstitute.com/section/association-between-mood-disorders-and-risk-of-covid-19-infection-hospitalization-and-death-2631-51532022-05-10never0.5https://psychopharmacologyinstitute.com/section/pediatric-ocd-comorbidity-with-depression-anxiety-disorders-and-asd-2626-51572022-03-17never0.5https://psychopharmacologyinstitute.com/section/guidelines-for-the-management-of-pediatric-ocd-2626-51592022-03-17never0.5https://psychopharmacologyinstitute.com/section/clinical-tips-for-treating-pediatric-ocd-long-term-follow-up-and-treatment-resistant-ocd-2626-51612022-03-17never0.5https://psychopharmacologyinstitute.com/section/assessing-and-treating-jane-2626-51632022-03-17never0.5https://psychopharmacologyinstitute.com/section/effect-of-zuranolone-vs-placebo-in-postpartum-depression-2632-51662023-03-13never0.5https://psychopharmacologyinstitute.com/section/the-canadian-network-for-mood-and-anxiety-treatments-canmat-task-force-recommendations-for-the-use-of-racemic-ketamine-in-adults-with-major-depressive-disorder-2632-51692022-05-06never0.5https://psychopharmacologyinstitute.com/section/relative-contraindications-to-antipsychotic-switching-2642-51722022-03-14never0.5https://psychopharmacologyinstitute.com/section/strategies-for-antipsychotic-switching-2642-51742022-03-14never0.5https://psychopharmacologyinstitute.com/section/types-of-antipsychotic-switching-between-po-agents-and-from-po-to-lai-2642-51752023-08-29never0.5https://psychopharmacologyinstitute.com/section/important-considerations-for-switching-to-clozapine-2642-51772022-03-14never0.5https://psychopharmacologyinstitute.com/section/treatment-implications-of-sleeprelated-problems-in-pediatric-anxiety-disorders-a-narrative-review-of-the-literature-2635-51812023-08-30never0.5https://psychopharmacologyinstitute.com/section/lithium-treatment-in-the-prevention-of-repeat-suicide-related-outcomes-in-veterans-with-major-depression-or-bipolar-disorder-2635-51822023-08-30never0.5https://psychopharmacologyinstitute.com/section/repetitive-transcranial-magnetic-stimulation-for-smoking-cessation-a-pivotal-multicenter-doubleblind-randomized-controlled-trial-2640-51862023-03-13never0.5https://psychopharmacologyinstitute.com/section/adjunctive-ketamine-with-relapse-prevention-based-psychological-therapy-in-the-treatment-of-alcohol-use-disorder-2640-51882022-03-28never0.5https://psychopharmacologyinstitute.com/section/understanding-patient-caregiver-and-enviromental-factors-2630-51922022-03-30never0.5https://psychopharmacologyinstitute.com/section/pharmacologic-and-nonpharmacologic-treatment-approaches-2630-51932022-03-30never0.5https://psychopharmacologyinstitute.com/section/overview-of-pharmacologic-treatment-for-bpsd-2630-51962022-03-30never0.5https://psychopharmacologyinstitute.com/section/antipsychotics-and-cholinesterase-inhibitors-for-bpsd-2630-51972022-03-30never0.5https://psychopharmacologyinstitute.com/section/study-of-mirtazapine-for-agitated-behaviors-in-dementia-symbad-a-randomised-double-blind-placebo-controlled-trial-2645-52002023-08-29never0.5https://psychopharmacologyinstitute.com/section/demographic-and-clinical-characteristics-of-patients-who-recommence-clozapine-following-therapy-interruptions-2645-52032022-04-22never0.5https://psychopharmacologyinstitute.com/section/diagnostic-evaluation-of-psychotic-symptoms-in-children-and-adolescents-2654-52072022-04-29never0.5https://psychopharmacologyinstitute.com/section/treatment-of-psychosis-and-schizophrenia-in-children-and-adolescents-antipsychotic-dosing-monitoring-and-side-effects-2654-52092023-08-29never0.5https://psychopharmacologyinstitute.com/section/additional-clinical-tips-for-treating-schizophrenia-in-children-and-adolescents-2654-52122023-08-29never0.5https://psychopharmacologyinstitute.com/section/long-term-follow-up-of-psychosis-and-schizophrenia-in-children-and-adolescents-2654-52142022-04-29never0.5https://psychopharmacologyinstitute.com/section/differential-diagnosis-of-explosive-behavior-mood-and-anxiety-disorders-and-disruptive-behavior-disorders-2641-52182022-05-30never0.5https://psychopharmacologyinstitute.com/section/management-of-acute-aggression-in-children-and-adolescents-2641-52202022-05-30never0.5https://psychopharmacologyinstitute.com/section/first-and-second-generation-antipsychotics-for-managing-explosive-behavior-2641-52222022-05-30never0.5https://psychopharmacologyinstitute.com/section/antidepressants-and-mood-stabilizers-for-managing-explosive-behavior-2641-52232022-05-30never0.5https://psychopharmacologyinstitute.com/section/rapid-tranquilization-of-the-agitated-patient-in-the-emergency-department-a-systematic-review-and-network-meta-analysis-2657-52282023-03-13never0.5https://psychopharmacologyinstitute.com/section/a-mini-review-of-pharmacologic-and-psychosocial-interventions-for-reducing-irritability-among-youth-with-adhd-2657-52292023-03-13never0.5https://psychopharmacologyinstitute.com/section/a-double-blind-placebo-controlled-study-of-brexpiprazole-for-the-treatment-of-borderline-personality-disorder-2658-52322023-03-14never0.5https://psychopharmacologyinstitute.com/section/association-between-fiasma-psychotropic-medications-and-reduced-risk-of-intubation-or-death-in-individuals-with-psychiatric-disorders-hospitalized-for-severe-covid-19-an-observational-multicenter-study-2658-52332023-08-28never0.5https://psychopharmacologyinstitute.com/section/challenges-in-prescribing-psychotropics-in-the-geriatric-population-and-mrs-ms-case-2668-52392022-06-30never0.5https://psychopharmacologyinstitute.com/section/using-ssris-and-snris-in-the-geriatric-population-2668-52402022-06-30never0.5https://psychopharmacologyinstitute.com/section/considerations-for-using-mood-stabilizers-in-the-geriatric-population-2668-52432022-08-08never0.5https://psychopharmacologyinstitute.com/section/considerations-for-using-benzodiazepines-and-benzodiazepine-receptor-agonists-in-the-geriatric-population-2668-52452022-06-30never0.5https://psychopharmacologyinstitute.com/section/naltrexone-potential-indications-and-administration-in-children-and-adolescents-2675-52502022-07-29never0.5https://psychopharmacologyinstitute.com/section/memantine-potential-indications-in-children-and-adolescents-2675-52512022-08-29never0.5https://psychopharmacologyinstitute.com/section/d-cycloserine-potential-indications-and-administration-in-children-and-adolescents-2675-52542022-07-29never0.5https://psychopharmacologyinstitute.com/section/potential-indications-of-melatonin-and-secretin-in-children-and-adolescents-2675-52572022-07-29never0.5https://psychopharmacologyinstitute.com/section/the-potential-use-of-folate-and-its-derivatives-in-treating-psychiatric-disorders-a-systematic-review-2670-52622023-08-30never0.5https://psychopharmacologyinstitute.com/section/association-between-physical-activity-and-risk-of-depression-a-systematic-review-and-meta-analysis-2670-52642023-03-14never0.5https://psychopharmacologyinstitute.com/section/metformin-for-the-prevention-of-clozapine-induced-weight-gain-a-retrospective-naturalistic-cohort-study-2683-52692022-08-25never0.5https://psychopharmacologyinstitute.com/section/the-serotonin-theory-of-depression-a-systematic-umbrella-review-of-the-evidence-2683-52702023-03-14never0.5https://psychopharmacologyinstitute.com/section/ocd-comorbidities-and-other-circumstances-variations-in-the-treatment-algorithm-2676-52722022-08-30never0.5https://psychopharmacologyinstitute.com/section/node-2-first-line-treatment-ssris-2676-52732022-10-07never0.5https://psychopharmacologyinstitute.com/section/node-2-potential-outcomes-after-the-first-trial-2676-52752022-08-30never0.5https://psychopharmacologyinstitute.com/section/node-4-ssri-augmentation-with-sga-2676-52772022-08-30never0.5https://psychopharmacologyinstitute.com/section/long-term-treatment-with-extended-release-methylphenidate-treatment-in-younger-children-2740-52842022-09-28never0.5https://psychopharmacologyinstitute.com/section/efficacy-and-safety-of-sgas-in-youth-with-bipolar-depression-2740-52852023-08-29never0.5https://psychopharmacologyinstitute.com/section/depression-in-adolescents-2741-52872022-10-14never0.5https://psychopharmacologyinstitute.com/section/ssris-and-risk-of-type-2-diabetes-in-children-and-adolescents-2741-52902022-09-30never0.5https://psychopharmacologyinstitute.com/section/early-antipsychotic-nonresponse-as-a-predictor-of-nonresponse-in-adolescents-with-psychosis-2742-52942023-08-30never0.5https://psychopharmacologyinstitute.com/section/impact-of-pharmacotherapy-of-childhood-onset-psychiatric-disorders-on-the-development-of-substance-use-disorders-2742-52962022-09-30never0.5https://psychopharmacologyinstitute.com/section/efficacy-and-safety-of-duloxetine-in-children-and-adolescents-with-mdd-in-japan-2743-52982022-11-01never0.5https://psychopharmacologyinstitute.com/section/long-term-effects-of-lithium-use-on-children-and-adolescents-2743-53002023-08-30never0.5https://psychopharmacologyinstitute.com/section/antidepressants-and-vertebral-and-hip-risk-fracture-an-updated-systematic-review-and-meta-analysis-2684-53032023-03-14never0.5https://psychopharmacologyinstitute.com/section/efficacy-of-bright-light-therapy-in-perinatal-depression-a-randomized-double-blind-placebo-controlled-study-2684-53062023-03-14never0.5https://psychopharmacologyinstitute.com/section/use-of-ginkgo-biloba-in-children-and-adolescents-2677-53082022-09-29never0.5https://psychopharmacologyinstitute.com/section/use-of-omega-3-fatty-acids-in-children-and-adolescents-2677-53092022-09-29never0.5https://psychopharmacologyinstitute.com/section/st-johns-wort-and-valerian-potential-indications-in-children-and-adolescents-2677-53102023-07-25never0.5https://psychopharmacologyinstitute.com/section/administration-of-n-acetylcysteine-and-s-adenosylmethionine-in-children-and-adolescents-2677-53132023-07-25never0.5https://psychopharmacologyinstitute.com/section/low-dose-olanzapine-for-treating-adolescents-with-anorexia-nervosa-2744-53192022-11-30never0.5https://psychopharmacologyinstitute.com/section/psychotropic-drugs-for-treating-nonsuicidal-selfinjury-in-the-youth-2744-53212022-11-30never0.5https://psychopharmacologyinstitute.com/section/impact-of-selected-initial-titration-schedules-on-safety-and-long-term-effectiveness-of-lamotrigine-for-the-treatment-of-mood-disorders-2685-53242023-08-30never0.5https://psychopharmacologyinstitute.com/section/estimates-of-the-minimal-important-difference-to-evaluate-the-clinical-significance-of-antidepressants-in-the-acute-treatment-of-moderate-to-severe-depression-part-2-2685-53262023-03-14never0.5https://psychopharmacologyinstitute.com/section/managing-clozapine-related-sialorrhea-2688-53292022-11-08never0.5https://psychopharmacologyinstitute.com/section/managing-clozapine-related-constipation-2688-53302022-10-27never0.5https://psychopharmacologyinstitute.com/section/managing-clozapine-related-orthostasis-2688-53312022-10-27never0.5https://psychopharmacologyinstitute.com/section/diagnosing-rem-sleep-behavior-disorder-2644-53412022-11-30never0.5https://psychopharmacologyinstitute.com/section/prevalence-assessment-and-management-of-rbd-2644-53432022-11-30never0.5https://psychopharmacologyinstitute.com/section/a-clinical-case-and-exclusive-videos-on-rbd-and-rls-2644-53472022-11-30never0.5https://psychopharmacologyinstitute.com/section/lamotrigine-and-lithium-combination-for-treatment-of-rapid-cycling-bipolar-disorder-results-from-meta-analysis-2692-53492023-08-30never0.5https://psychopharmacologyinstitute.com/section/microdosing-with-psilocybin-mushrooms-a-double-blind-placebo-controlled-study-2692-53502022-11-30never0.5https://psychopharmacologyinstitute.com/section/depression-and-mediterranean-style-diet-2689-53562022-12-30never0.5https://psychopharmacologyinstitute.com/section/rationale-for-micronutrient-supplementation-in-mental-illness-2689-53582022-12-30never0.5https://psychopharmacologyinstitute.com/section/an-overview-of-standard-treatment-vs-cam-for-adhd-2689-53602022-12-30never0.5https://psychopharmacologyinstitute.com/section/neurologic-and-psychiatric-risk-trajectories-after-sars-cov-2-infection-an-analysis-of-2-year-retrospective-cohort-studies-including-1284437-patients-2693-53672023-01-24never0.5https://psychopharmacologyinstitute.com/section/intermittent-selective-serotonin-reuptake-inhibitors-for-premenstrual-syndromes-a-systematic-review-and-meta-analysis-of-randomized-trials-2693-53702023-08-28never0.5https://psychopharmacologyinstitute.com/section/barriers-to-metabolic-monitoring-of-sgas-in-youth-2745-53732024-02-14never0.5https://psychopharmacologyinstitute.com/section/nonstimulant-treatments-for-adhd-2745-53742022-12-30never0.5https://psychopharmacologyinstitute.com/section/treatment-of-motor-hyperactivity-and-inattention-in-asd-stimulants-2695-53772023-02-01never0.5https://psychopharmacologyinstitute.com/section/treatment-of-irritability-in-asd-risperidone-and-aripiprazole-2695-53812023-02-01never0.5https://psychopharmacologyinstitute.com/section/treatment-of-sleep-disturbances-in-asd-melatonin-and-other-strategies-2695-53842023-02-01never0.5https://psychopharmacologyinstitute.com/section/antipsychotic-augmentation-with-n-acetylcysteine-for-patients-with-schizophrenia-2705-53872023-03-14never0.5https://psychopharmacologyinstitute.com/section/sublingual-dexmedetomidine-for-the-treatment-of-acute-agitation-in-adults-with-schizophrenia-or-schizoaffective-disorder-a-randomized-placebo-controlled-trial-2705-53902023-03-14never0.5https://psychopharmacologyinstitute.com/section/psychotropic-prescriptions-in-youth-during-covid-19-pandemic-2746-53942023-01-25never0.5https://psychopharmacologyinstitute.com/section/efficacy-and-safety-of-lisdexamfetamine-in-preschool-children-with-adhd-2746-53952023-02-01never0.5https://psychopharmacologyinstitute.com/section/c-reactive-protein-could-predict-the-efficacy-of-ssris-in-clinical-practice-a-cohort-study-of-large-samples-in-the-real-world-2706-54002024-02-28never0.5https://psychopharmacologyinstitute.com/section/effect-of-anxiolytic-drug-silexan-on-sleep-a-narrative-review-2706-54012024-02-28never0.5https://psychopharmacologyinstitute.com/section/impact-of-adhd-medications-on-anxiety-and-depression-in-youth-2747-54032023-02-28never0.5https://psychopharmacologyinstitute.com/section/ketamine-for-adolescent-depression-2747-54052023-02-28never0.5https://psychopharmacologyinstitute.com/section/diagnosing-sleep-related-eating-disorder-sred-2698-54082023-02-28never0.5https://psychopharmacologyinstitute.com/section/medication-induced-sred-sleepwalking-and-sleepdriving-2698-54092023-02-28never0.5https://psychopharmacologyinstitute.com/section/zolpidem-induced-sleepwalking-and-sred-2698-54112023-02-28never0.5https://psychopharmacologyinstitute.com/section/understanding-tic-disorders-2700-54172023-03-31never0.5https://psychopharmacologyinstitute.com/section/tic-disorders-and-psychiatric-comorbidities-2700-54202023-03-31never0.5https://psychopharmacologyinstitute.com/section/treatment-optimization-for-tic-disorders-2700-54252023-03-31never0.5https://psychopharmacologyinstitute.com/section/associations-between-antipsychotic-use-substance-use-and-relapse-risk-in-patients-with-schizophrenia-real-world-evidence-from-2-national-cohorts-2707-54292024-02-28never0.5https://psychopharmacologyinstitute.com/section/effect-of-pharmacogenomic-testing-for-druggene-interactions-on-medication-selection-and-remission-of-symptoms-in-major-depressive-disorder-the-prime-care-randomized-clinical-trial-2707-54332024-02-28never0.5https://psychopharmacologyinstitute.com/section/risk-of-cardiovascular-diseases-associated-with-medications-used-in-adhd-2748-54352023-03-31never0.5https://psychopharmacologyinstitute.com/section/disparities-in-pharmacologic-restraint-use-in-pediatric-emergency-departments-2748-54382023-03-31never0.5https://psychopharmacologyinstitute.com/section/treating-depressive-disorders-in-patients-with-cancer-2724-54422023-04-28never0.5https://psychopharmacologyinstitute.com/section/treating-anxiety-disorders-in-patients-with-cancer-2724-54442023-04-29never0.5https://psychopharmacologyinstitute.com/section/management-of-delirium-in-patients-with-cancer-2724-54482023-04-28never0.5https://psychopharmacologyinstitute.com/section/haloperidol-for-the-treatment-of-delirium-in-icu-patients-2708-54502024-02-28never0.5https://psychopharmacologyinstitute.com/section/risk-of-cardiovascular-diseases-associated-with-medications-used-in-attention-deficithyperactivity-disorder-a-systematic-review-and-meta-analysis-2708-54522024-02-28never0.5https://psychopharmacologyinstitute.com/section/reported-side-effects-associated-with-medication-nonadherence-among-youth-with-adhd-2749-54552023-04-26never0.5https://psychopharmacologyinstitute.com/section/psychopharmacologic-treatment-algorithms-for-bipolar-disorder-in-youth-2749-54572023-04-26never0.5https://psychopharmacologyinstitute.com/section/using-clozapine-for-treatment-resistant-psychosis-and-mood-disorders-2733-54612024-08-27never0.5https://psychopharmacologyinstitute.com/section/initiating-and-optimizing-clozapine-2733-54652024-08-27never0.5https://psychopharmacologyinstitute.com/section/managing-cardiac-and-metabolic-adverse-effects-of-clozapine-2733-54682024-08-27never0.5https://psychopharmacologyinstitute.com/section/melatonin-use-and-the-risk-of-self-harm-and-unintentional-injuries-in-youth-2750-54722023-05-30never0.5https://psychopharmacologyinstitute.com/section/safety-and-tolerability-of-cariprazine-in-pediatric-patients-2750-54742023-05-30never0.5https://psychopharmacologyinstitute.com/section/comparative-efficacy-safety-and-acceptability-of-pimavanserin-and-other-atypical-antipsychotics-for-parkinsons-disease-psychosis-systematic-review-and-network-meta-analysis-2726-54772024-02-28never0.5https://psychopharmacologyinstitute.com/section/olanzapinesamidorphan-in-young-adults-with-schizophrenia-schizophreniform-disorder-or-bipolar-i-disorder-who-are-early-in-their-illness-results-of-the-randomized-controlled-enlighten-early-study-2726-54812024-02-28never0.5https://psychopharmacologyinstitute.com/section/diagnosing-fibromyalgia-2734-54842024-08-27never0.5https://psychopharmacologyinstitute.com/section/pharmacologic-therapies-for-fibromyalgia-2734-54872024-08-27never0.5https://psychopharmacologyinstitute.com/section/nonpharmacologic-therapies-for-fibromyalgia-2734-54902024-08-27never0.5https://psychopharmacologyinstitute.com/section/metformin-for-weight-gain-in-youth-on-atypical-antipsychotics-2751-54942023-06-30never0.5https://psychopharmacologyinstitute.com/section/prescribing-stimulants-for-youth-with-adhd-and-co-occurring-cannabis-use-2751-54952023-06-28never0.5https://psychopharmacologyinstitute.com/section/cades-disease-and-beyond-misdiagnosis-antidepressant-use-and-a-proposed-definition-for-bipolar-spectrum-disorder-2731-54982024-02-28never0.5https://psychopharmacologyinstitute.com/section/canadian-network-for-mood-and-anxiety-treatments-canmat-and-international-society-for-bipolar-disorders-isbd-recommendations-for-the-management-of-patients-with-bipolar-disorder-with-mixed-presentations-2731-54992024-02-28never0.5https://psychopharmacologyinstitute.com/section/effect-of-brexanolone-on-postpartum-depressive-symptoms-anxiety-and-insomnia-2737-55032024-02-28never0.5https://psychopharmacologyinstitute.com/section/the-impact-of-colony-stimulating-factor-on-clozapine-rechallenge-outcomes-2737-55072024-02-28never0.5https://psychopharmacologyinstitute.com/section/managing-adverse-effects-of-antidepressants-in-youth-2752-55082023-07-24never0.5https://psychopharmacologyinstitute.com/section/ages-impact-on-antidepressant-response-2752-55092023-07-24never0.5https://psychopharmacologyinstitute.com/section/bsms-safety-and-tolerability-2729-55152023-08-01never0.5https://psychopharmacologyinstitute.com/section/bsms-and-drug-interactions-2729-55182023-08-01never0.5https://psychopharmacologyinstitute.com/section/practical-tips-for-using-bsms-in-the-clinical-practice-2729-55192023-08-01never0.5https://psychopharmacologyinstitute.com/section/clinical-cases-2729-55232023-08-15never0.5https://psychopharmacologyinstitute.com/section/risks-of-using-lithium-in-pregnancy-2766-55272023-08-29never0.5https://psychopharmacologyinstitute.com/section/bipolar-disorder-during-pregnancy-management-of-lithium-2766-55282023-08-29never0.5https://psychopharmacologyinstitute.com/section/risks-of-using-antipsychotics-during-pregnancy-2766-55322023-08-29never0.5https://psychopharmacologyinstitute.com/section/guiding-principles-for-treating-bipolar-disorder-during-pregnancy-2766-55342023-08-29never0.5https://psychopharmacologyinstitute.com/section/risk-of-major-malformations-following-first-trimester-exposure-to-olanzapine-2753-55382023-08-29never0.5https://psychopharmacologyinstitute.com/section/use-of-lithium-in-pediatric-bipolar-disorders-and-externalizing-childhood-related-disorders-2753-55412023-08-29never0.5https://psychopharmacologyinstitute.com/section/use-of-nsaids-for-delirium-risk-reduction-2738-55422024-02-28never0.5https://psychopharmacologyinstitute.com/section/zuranolone-for-the-treatment-of-postpartum-depression-2738-55442024-02-28never0.5https://psychopharmacologyinstitute.com/section/relapse-prevention-strategies-for-depression-and-anxiety-in-remitted-youth-2779-55472023-09-19never0.5https://psychopharmacologyinstitute.com/section/antipsychotics-in-the-treatment-of-youth-with-anorexia-nervosa-2779-55482023-09-19never0.5https://psychopharmacologyinstitute.com/section/understanding-the-problem-of-treatment-resistance-2767-55542023-09-26never0.5https://psychopharmacologyinstitute.com/section/an-introduction-to-psychodynamic-psychopharmacology-2767-55572023-09-26never0.5https://psychopharmacologyinstitute.com/section/attending-the-patients-ambivalence-2767-55612023-09-26never0.5https://psychopharmacologyinstitute.com/section/cultivating-a-therapeutic-alliance-2767-55622023-09-26never0.5https://psychopharmacologyinstitute.com/section/tobacco-use-nicotine-dependence-and-cessation-among-adults-with-psychosis-2774-55662024-02-28never0.5https://psychopharmacologyinstitute.com/section/risk-of-irreversible-postssri-sexual-dysfunction-with-antidepressants-2774-55682024-02-28never0.5https://psychopharmacologyinstitute.com/section/neonatal-and-pregnancy-complications-following-maternal-depression-or-antidepressant-exposure-2775-55712024-02-28never0.5https://psychopharmacologyinstitute.com/section/antipsychotic-safety-in-liver-disease-2775-55742024-02-28never0.5https://psychopharmacologyinstitute.com/section/in-utero-exposure-to-adhd-medication-and-long-term-offspring-outcomes-2780-55772023-10-31never0.5https://psychopharmacologyinstitute.com/section/is-fish-oil-effective-in-youth-depression-2780-55782023-11-23never0.5https://psychopharmacologyinstitute.com/section/exploring-the-evidence-of-n-acetyl-cysteine-nac-for-mood-disorders-2768-55822023-10-31never0.5https://psychopharmacologyinstitute.com/section/cannabidiol-evidence-for-psychiatric-disorders-and-recommendations-for-using-it-2768-55852023-10-31never0.5https://psychopharmacologyinstitute.com/section/ashwagandha-asw-potential-indications-and-administration-in-psychiatric-disorders-2768-55872023-10-31never0.5https://psychopharmacologyinstitute.com/section/potential-combinations-of-natural-medication-for-psychiatric-disorders-2768-55882023-10-31never0.5https://psychopharmacologyinstitute.com/section/clozapine-and-its-augmentation-with-ect-in-ultra-treatment-resistant-schizophrenia-2776-55922024-02-27never0.5https://psychopharmacologyinstitute.com/section/risk-for-suicide-attempts-and-suicide-associated-with-benzodiazepines-2776-55932024-02-27never0.5https://psychopharmacologyinstitute.com/section/effect-of-methylphenidate-on-pain-perception-thresholds-in-children-with-adhd-2781-55962023-12-25never0.5https://psychopharmacologyinstitute.com/section/adoption-of-vaping-cessation-methods-by-us-adolescents-2781-55992023-11-29never0.5https://psychopharmacologyinstitute.com/section/understanding-the-relationship-between-insomnia-disorder-and-mdd-2765-56022023-12-01never0.5https://psychopharmacologyinstitute.com/section/pharmacologic-interventions-for-insomnia-benzodiazepines-and-non-benzodiazepine-hypnotics-2765-56052023-12-01never0.5https://psychopharmacologyinstitute.com/section/other-pharmacologic-interventions-for-insomnia-2765-56062023-12-01never0.5https://psychopharmacologyinstitute.com/section/treatment-strategies-for-managing-insomnia-in-mdd-2765-56072023-12-01never0.5https://psychopharmacologyinstitute.com/section/the-science-of-the-art-of-psychopharmacotherapy-2784-56112023-12-28never0.5https://psychopharmacologyinstitute.com/section/the-biological-theory-of-illness-and-stigma-2784-56122023-12-28never0.5https://psychopharmacologyinstitute.com/section/pharmacotherapy-alliance-treatment-preferences-and-communication-2784-56132023-12-28never0.5https://psychopharmacologyinstitute.com/section/psychotherapy-skills-in-everyday-practice-ordinary-medical-psychotherapy-2784-56142023-12-28never0.5https://psychopharmacologyinstitute.com/section/psychedelics-as-transformative-therapeutics-2777-56192024-02-27never0.5https://psychopharmacologyinstitute.com/section/use-of-daridorexant-for-the-management-of-chronic-insomnia-2777-56212024-02-27never0.5https://psychopharmacologyinstitute.com/section/comparative-safety-of-oral-antipsychotics-for-adverse-events-in-adults-after-surgery-2778-56252024-01-11never0.5https://psychopharmacologyinstitute.com/section/medical-cannabis-in-the-treatment-of-parkinsons-disease-2778-56262024-01-11never0.5https://psychopharmacologyinstitute.com/section/the-role-of-escitalopram-in-treating-generalized-anxiety-disorder-in-youth-2782-56282024-01-18never0.5https://psychopharmacologyinstitute.com/section/efficacy-of-risperidone-as-treatment-for-anorexia-nervosa-2782-56322024-01-19never0.5https://psychopharmacologyinstitute.com/section/understanding-lamotrigine-mechanisms-and-titration-schedule-2791-56342025-06-20never0.5https://psychopharmacologyinstitute.com/section/lamotrigine-side-effects-and-special-considerations-2791-56352024-02-01never0.5https://psychopharmacologyinstitute.com/section/lamotrigine-effect-on-qtc-prolongation-and-qrs-widening-2791-56372024-02-01never0.5https://psychopharmacologyinstitute.com/section/strategies-for-safe-usage-and-proper-monitoring-of-lamotrigine-2791-56392024-02-01never0.5https://psychopharmacologyinstitute.com/section/other-psychiatric-diagnoses-in-agitated-patients-mood-and-substance-use-disorders-2786-56452024-02-22never0.5https://psychopharmacologyinstitute.com/section/nonpharmacologic-strategies-for-managing-agitation-verbal-de-escalation-2786-56462024-02-22never0.5https://psychopharmacologyinstitute.com/section/pharmacologic-strategies-for-managing-agitation-general-recommendations-and-treatments-goals-2786-56472024-02-22never0.5https://psychopharmacologyinstitute.com/section/the-role-of-benzodiazepines-and-dexmedetomidine-in-managing-agitation-2786-56492024-02-22never0.5https://psychopharmacologyinstitute.com/section/efficacy-of-memantine-in-treating-trichotillomania-and-skin-picking-disorder-2788-56542024-02-22never0.5https://psychopharmacologyinstitute.com/section/psychiatric-disorders-and-subsequent-risk-of-cardiovascular-disease-2788-56552024-02-21never0.5https://psychopharmacologyinstitute.com/section/efficacy-of-probiotics-in-treating-adhd-symptoms-2783-56582024-03-20never0.5https://psychopharmacologyinstitute.com/section/electroconvulsive-therapy-for-adolescents-with-severe-depression-and-suicidality-2783-56592024-03-20never0.5https://psychopharmacologyinstitute.com/section/stopping-benzodiazepines-and-z-drugs-in-hospitalized-elderly-patients-2794-56642024-03-20never0.5https://psychopharmacologyinstitute.com/section/is-high-dose-olanzapine-an-option-for-treatment-resistant-schizophrenia-2794-56662024-03-30never0.5https://psychopharmacologyinstitute.com/section/assessing-the-potential-side-effects-of-tms-2792-56702024-03-28never0.5https://psychopharmacologyinstitute.com/section/exploring-the-evidence-of-tms-for-depression-2792-56712024-03-28never0.5https://psychopharmacologyinstitute.com/section/exploring-the-evidence-of-tms-for-ocd-2792-56722024-03-28never0.5https://psychopharmacologyinstitute.com/section/optimizing-patient-selection-for-tms-treatment-2792-56742024-03-28never0.5https://psychopharmacologyinstitute.com/section/appropriate-benzodiazepine-use-indications-and-optimal-selection-2797-56802024-05-01never0.5https://psychopharmacologyinstitute.com/section/understanding-the-major-risks-of-benzodiazepine-use-2797-56822024-04-25never0.5https://psychopharmacologyinstitute.com/section/benzodiazepine-use-disorder-2797-56842024-04-25never0.5https://psychopharmacologyinstitute.com/section/consequences-of-benzodiazepine-use-in-pregnancy-breastfeeding-and-adolescence-2797-56862024-04-25never0.5https://psychopharmacologyinstitute.com/section/antipsychotic-dose-reduction-in-schizophrenia-insights-from-the-radar-trial-2801-56892024-04-23never0.5https://psychopharmacologyinstitute.com/section/famotidine-for-covid-19-brain-fog-a-promising-treatment-option-2801-56912024-04-23never0.5https://psychopharmacologyinstitute.com/section/long-term-effects-of-methylphenidate-on-sleep-in-children-and-adolescents-with-adhd-2789-56952024-05-23never0.5https://psychopharmacologyinstitute.com/section/cardiac-and-metabolic-safety-profile-of-antipsychotics-in-youth-2789-56972024-05-23never0.5https://psychopharmacologyinstitute.com/section/xanomeline-trospium-karxt-shows-efficacy-in-phase-3-trial-for-schizophrenia-2802-57002024-05-30never0.5https://psychopharmacologyinstitute.com/section/iloperidone-a-potential-treatment-option-for-bipolar-mania-2802-57042024-05-30never0.5https://psychopharmacologyinstitute.com/section/benzodiazepine-deprescription-indications-benefits-and-risks-2798-57062024-06-01never0.5https://psychopharmacologyinstitute.com/section/understanding-the-principles-of-benzodiazepine-tapering-2798-57072024-06-01never0.5https://psychopharmacologyinstitute.com/section/techniques-for-successful-benzodiazepine-tapering-2798-57082024-06-01never0.5https://psychopharmacologyinstitute.com/section/beyond-benzodiazepine-discontinuation-understanding-life-effects-and-support-strategies-2798-57112024-06-01never0.5https://psychopharmacologyinstitute.com/section/managing-bipolar-mania-with-mixed-features-sgas-2814-57162024-06-29never0.5https://psychopharmacologyinstitute.com/section/choosing-between-valproate-or-lithium-augmentation-for-bipolar-mania-with-mixed-features-2814-57172024-06-29never0.5https://psychopharmacologyinstitute.com/section/lithium-for-bipolar-mania-without-mixed-features-2814-57182024-06-29never0.5https://psychopharmacologyinstitute.com/section/augmenting-with-sgas-after-unsatisfactory-response-to-lithium-in-bipolar-mania-2814-57192024-06-29never0.5https://psychopharmacologyinstitute.com/section/insomnia-in-the-elderly-do-sedatives-increase-or-decrease-fall-risk-2809-57242024-06-29never0.5https://psychopharmacologyinstitute.com/section/antipsychotic-withdrawal-syndrome-symptoms-risks-and-prevention-strategies-2809-57262024-06-29never0.5https://psychopharmacologyinstitute.com/section/tailored-patient-assessment-a-key-to-effective-oud-treatment-2807-57302024-07-30never0.5https://psychopharmacologyinstitute.com/section/methadone-for-managing-oud-2807-57312024-07-30never0.5https://psychopharmacologyinstitute.com/section/buprenorphine-for-managing-oud-2807-57322024-07-30never0.5https://psychopharmacologyinstitute.com/section/examining-the-efficacy-of-extended-release-naltrexone-oud-2807-57332024-07-30never0.5https://psychopharmacologyinstitute.com/section/can-ssris-be-safely-prescribed-with-oral-anticoagulants-2817-57372024-07-31never0.5https://psychopharmacologyinstitute.com/section/do-benzodiazepine-users-escalate-doses-over-time-2817-57382024-07-31never0.5https://psychopharmacologyinstitute.com/section/can-donanemab-slow-alzheimers-progression-2818-57422024-08-27never0.5https://psychopharmacologyinstitute.com/section/does-clozapines-agranulocytosis-risk-persist-beyond-initial-treatment-period-2818-57432024-08-27never0.5https://psychopharmacologyinstitute.com/section/the-mechanisms-and-effects-of-psychedelics-2813-57482024-08-31never0.5https://psychopharmacologyinstitute.com/section/how-psychedelics-influence-brain-networks-2813-57492024-08-31never0.5https://psychopharmacologyinstitute.com/section/examining-the-combined-use-of-psychedelics-and-psychiatric-drugs-2813-57502024-08-31never0.5https://psychopharmacologyinstitute.com/section/psychedelic-assisted-therapy-in-clinical-practice-2813-57512024-08-31never0.5https://psychopharmacologyinstitute.com/section/which-antidepressants-have-the-highest-risk-of-discontinuation-symptoms-2830-57562024-10-01never0.5https://psychopharmacologyinstitute.com/section/olanzapine-induced-weight-gain-can-akkermansia-muciniphila-help-2830-57572024-09-25never0.5https://psychopharmacologyinstitute.com/section/treatment-algorithm-for-adult-adhd-2835-57652024-10-01never0.5https://psychopharmacologyinstitute.com/section/pharmacologic-treatments-for-adult-adhd-focus-on-stimulants-2835-57662024-10-01never0.5https://psychopharmacologyinstitute.com/section/stimulants-clinical-considerations-preventing-abuse-and-red-flags-2835-57672024-10-01never0.5https://psychopharmacologyinstitute.com/section/long-acting-antipsychotics-an-option-for-women-with-schizophrenia-2831-57712024-10-25never0.5https://psychopharmacologyinstitute.com/section/can-vitamin-d-deficiency-increase-the-risk-of-alzheimers-disease-2831-57722024-10-25never0.5https://psychopharmacologyinstitute.com/section/can-lithium-protect-against-osteoporosis-2831-57732024-10-25never0.5https://psychopharmacologyinstitute.com/section/distinguishing-postpartum-ocd-from-postpartum-psychosis-2826-57802024-10-25never0.5https://psychopharmacologyinstitute.com/section/postpartum-depression-pharmacologic-considerations-for-breastfeeding-mothers-2826-57832024-10-25never0.5https://psychopharmacologyinstitute.com/section/the-role-of-brexanolone-and-zuranolone-in-postpartum-depression-2826-57852024-10-25never0.5https://psychopharmacologyinstitute.com/section/postpartum-psychosis-pharmacologic-strategies-2826-57862024-10-25never0.5https://psychopharmacologyinstitute.com/section/clozapine-the-hidden-risks-of-ileus-and-pneumonia-2837-57882024-11-26never0.5https://psychopharmacologyinstitute.com/section/can-topiramate-replace-fda-approved-medications-for-alcohol-use-disorder-2837-57892024-11-30never0.5https://psychopharmacologyinstitute.com/section/pharmacogenetic-tests-that-matter-in-psychiatric-practice-2827-57952024-11-30never0.5https://psychopharmacologyinstitute.com/section/pharmacogenetics-guided-dosing-strategies-for-poor-and-rapid-metabolizers-2827-57962024-11-30never0.5https://psychopharmacologyinstitute.com/section/pharmacogenetic-panels-do-they-really-work-2827-57972024-11-30never0.5https://psychopharmacologyinstitute.com/section/clozapine-and-ocd-like-symptoms-whats-the-connection-2842-58042024-12-30never0.5https://psychopharmacologyinstitute.com/section/is-valproate-weight-gain-dose-dependent-2842-58052024-12-30never0.5https://psychopharmacologyinstitute.com/section/pregnancys-impact-on-medication-efficacy-and-dosing-considerations-2846-58092025-01-10never0.5https://psychopharmacologyinstitute.com/section/lithium-in-pregnancy-and-breastfeeding-2846-58112024-12-31never0.5https://psychopharmacologyinstitute.com/section/ssri-treatment-during-pregnancy-a-clinical-case-2846-58122024-12-31never0.5https://psychopharmacologyinstitute.com/section/pregnancy-adhd-and-stimulants-making-an-informed-choice-2846-58142024-12-31never0.5https://psychopharmacologyinstitute.com/section/pneumonia-in-schizophrenia-which-antipsychotics-pose-the-highest-risk-for-2843-58172025-01-31never0.5https://psychopharmacologyinstitute.com/section/antipsychotic-induced-weight-gain-best-management-strategies-2843-58182025-01-31never0.5https://psychopharmacologyinstitute.com/section/what-is-the-optimal-therapeutic-range-for-lithium-in-bipolar-disorder-2843-58192025-01-31never0.5https://psychopharmacologyinstitute.com/section/selecting-the-initial-depression-treatment-2864-58242025-02-01never0.5https://psychopharmacologyinstitute.com/section/complementary-and-alternative-medicine-for-depression-canmat-recommendations-2864-58252025-02-01never0.5https://psychopharmacologyinstitute.com/section/pharmacologic-management-of-difficult-to-treat-depression-first-second-and-third-line-options-2864-58282025-02-01never0.5https://psychopharmacologyinstitute.com/section/can-glp-1-agonists-treat-alcohol-use-disorder-2847-58322025-02-27never0.5https://psychopharmacologyinstitute.com/section/which-antidepressants-cause-the-most-weight-gain-2847-58332025-02-27never0.5https://psychopharmacologyinstitute.com/section/antipsychotic-induced-weight-gain-prevention-and-management-2880-58392025-02-27never0.5https://psychopharmacologyinstitute.com/section/managing-hyperprolactinemia-and-sexual-side-effects-from-antipsychotic-use-2880-58442025-02-27never0.5https://psychopharmacologyinstitute.com/section/addressing-cardiac-side-effects-of-antipsychotic-treatment-2880-58452025-02-27never0.5https://psychopharmacologyinstitute.com/section/antipsychotic-induced-gastrointestinal-issues-sialorrhea-and-constipation-2880-58472025-02-27never0.5https://psychopharmacologyinstitute.com/section/long-acting-injectables-superior-for-reducing-mortality-in-schizophrenia-2865-58492025-03-25never0.5https://psychopharmacologyinstitute.com/section/bipolar-disorder-maintenance-whats-the-optimal-dose-range-2865-58502025-03-31never0.5https://psychopharmacologyinstitute.com/section/alzheimers-disease-olanzapine-vs-risperidone-for-bpsd-2865-58512025-03-25never0.5https://psychopharmacologyinstitute.com/section/bulimia-nervosa-medications-that-work-2883-58552025-03-28never0.5https://psychopharmacologyinstitute.com/section/binge-eating-disorder-pharmacotherapy-antidepressants-and-anticonvulsants-2883-58592025-03-28never0.5https://psychopharmacologyinstitute.com/section/binge-eating-disorder-pharmacotherapy-lisdexamfetamine-2883-58602025-03-28never0.5https://psychopharmacologyinstitute.com/section/lurasidone-for-bipolar-depression-what-is-the-optimal-dose-2866-58632025-04-23never0.5https://psychopharmacologyinstitute.com/section/alcohol-use-disorder-should-disulfiram-be-first-line-2866-58642025-04-23never0.5https://psychopharmacologyinstitute.com/section/melatonin-trazodone-or-doxepin-for-sleep-disorders-2866-58652025-04-23never0.5https://psychopharmacologyinstitute.com/section/baseline-testing-monitoring-and-optimal-dosing-of-lithium-2889-58692025-04-29never0.5https://psychopharmacologyinstitute.com/section/managing-renal-side-effects-of-lithium-therapy-2889-58702025-04-29never0.5https://psychopharmacologyinstitute.com/section/how-to-mitigate-weight-gain-and-gastrointestinal-side-effects-of-lithium-2889-58712025-04-29never0.5https://psychopharmacologyinstitute.com/section/approaching-sexual-dysfunction-hair-loss-and-rashes-with-lithium-2889-58742025-04-29never0.5https://psychopharmacologyinstitute.com/section/schizophrenia-algorithm-selecting-an-antipsychotic-for-first-episodes-2867-58772025-05-28never0.5https://psychopharmacologyinstitute.com/section/do-ssri-side-effects-improve-over-time-2867-58782025-05-28never0.5https://psychopharmacologyinstitute.com/section/torsades-de-pointes-impact-of-antidepressants-and-antipsychotics-2867-58792025-05-28never0.5https://psychopharmacologyinstitute.com/section/understanding-when-to-prescribe-lais-2881-58832025-05-30never0.5https://psychopharmacologyinstitute.com/section/lais-in-practice-aripiprazole-olanzapine-2881-58882025-05-30never0.5https://psychopharmacologyinstitute.com/section/lais-in-practice-paliperidone-risperidone-2881-58892025-05-30never0.5https://psychopharmacologyinstitute.com/section/lumateperone-for-depression-with-mixed-features-is-it-effective-2874-58922025-07-01never0.5https://psychopharmacologyinstitute.com/section/antipsychotic-induced-weight-gain-are-glp-1-agonists-effective-2874-58932025-07-01never0.5https://psychopharmacologyinstitute.com/section/treatment-resistant-depression-lithium-vs-quetiapine-for-augmentation-2874-58942025-07-01never0.5https://psychopharmacologyinstitute.com/section/catatonia-diagnosis-the-lorazepam-challenge-2911-58992025-06-30never0.5https://psychopharmacologyinstitute.com/section/catatonia-pharmacotherapy-the-role-of-benzodiazepines-2911-59022025-06-30never0.5https://psychopharmacologyinstitute.com/section/nmda-antagonists-for-catatonia-management-amantadine-memantine-and-ketamine-2911-59042025-06-30never0.5https://psychopharmacologyinstitute.com/section/how-to-work-up-a-case-of-insomnia-2516-48572022-03-17never0.5https://psychopharmacologyinstitute.com/section/understanding-cannabis-in-psychiatry-pharmacology-and-synthetic-cannabinoids-2054-40612025-04-16never0.5https://psychopharmacologyinstitute.com/section/synthetic-cannabinoids-how-to-manage-intoxication-and-withdrawal-2268-43882022-03-17never0.5https://psychopharmacologyinstitute.com/section/diagnosis-how-to-recognize-an-opioid-use-disorder-2037-46842025-04-16never0.5https://psychopharmacologyinstitute.com/section/how-to-talk-to-patients-about-sleep-2516-48602022-03-17never0.5https://psychopharmacologyinstitute.com/section/current-medical-use-and-therapeutic-potential-2054-40572025-04-16never0.5https://psychopharmacologyinstitute.com/section/pharmacotherapy-for-insomnia-2516-48622022-03-17never0.5https://psychopharmacologyinstitute.com/section/buprenorphine-for-opioid-use-disorder-mechanism-of-action-2037-40022025-04-16never0.5https://psychopharmacologyinstitute.com/section/buprenorphine-formulations-a-practical-summary-for-clinicians-2037-40032025-04-16never0.5https://psychopharmacologyinstitute.com/section/novel-synthetic-opioids-clinical-manifestations-diagnosis-and-treatment-2268-43922022-03-17never0.5https://psychopharmacologyinstitute.com/author/david-osser-8672025-06-06never0.2https://psychopharmacologyinstitute.com/author/joji-suzuki-8682025-06-06never0.2https://psychopharmacologyinstitute.com/author/rajesh-tampi-8692025-06-06never0.2https://psychopharmacologyinstitute.com/author/flavio-guzman-8702025-06-06never0.2https://psychopharmacologyinstitute.com/author/erick-h-turner-8712025-06-06never0.2https://psychopharmacologyinstitute.com/author/rajnish-mago-8722025-06-10never0.2https://psychopharmacologyinstitute.com/author/paul-morrison-8732025-06-10never0.2https://psychopharmacologyinstitute.com/author/sandra-a-jacobson-8752025-06-06never0.2https://psychopharmacologyinstitute.com/author/michael-d-jibson-8762025-06-10never0.2https://psychopharmacologyinstitute.com/author/james-phelps-8772025-06-06never0.2https://psychopharmacologyinstitute.com/author/jonathan-m-meyer-8782025-06-06never0.2https://psychopharmacologyinstitute.com/author/james-levenson-8792025-06-06never0.2https://psychopharmacologyinstitute.com/author/david-nutt-8802025-06-06never0.2https://psychopharmacologyinstitute.com/author/david-mischoulon-8812025-06-06never0.2https://psychopharmacologyinstitute.com/author/simon-kung-8822025-06-06never0.2https://psychopharmacologyinstitute.com/author/vivien-k-burt-8832025-06-06never0.2https://psychopharmacologyinstitute.com/author/philip-cowen-8842025-06-06never0.2https://psychopharmacologyinstitute.com/author/wegdan-rashad-8862025-06-06never0.2https://psychopharmacologyinstitute.com/author/david-a-gorelick-8872025-07-11never0.2https://psychopharmacologyinstitute.com/author/david-veale-8882025-06-06never0.2https://psychopharmacologyinstitute.com/author/derek-tracy-8892025-06-06never0.2https://psychopharmacologyinstitute.com/author/joseph-f-goldberg-8902025-06-10never0.2https://psychopharmacologyinstitute.com/author/dana-wang-8912025-06-06never0.2https://psychopharmacologyinstitute.com/author/scott-r-beach-8922025-07-11never0.2https://psychopharmacologyinstitute.com/author/othman-m-mohammad-8932025-06-06never0.2https://psychopharmacologyinstitute.com/author/paul-zarkowski-8942025-07-15never0.2https://psychopharmacologyinstitute.com/author/martha-sajatovic-8952025-06-06never0.2https://psychopharmacologyinstitute.com/author/gregory-pontone-8972025-06-06never0.2https://psychopharmacologyinstitute.com/author/samuel-wilkinson-8982025-06-06never0.2https://psychopharmacologyinstitute.com/author/marlene-p-freeman-8992025-06-06never0.2https://psychopharmacologyinstitute.com/author/cristina-cusin-9002025-06-06never0.2https://psychopharmacologyinstitute.com/author/to-be-announced-9012020-01-28never0.2https://psychopharmacologyinstitute.com/author/steven-l-dubovsky-9022025-06-06never0.2https://psychopharmacologyinstitute.com/author/charles-f-reynolds-iii-9032025-06-06never0.2https://psychopharmacologyinstitute.com/author/robert-hudak-9042025-06-06never0.2https://psychopharmacologyinstitute.com/author/oscar-bukstein-9052025-06-06never0.2https://psychopharmacologyinstitute.com/author/lauren-osborne-9062025-06-06never0.2https://psychopharmacologyinstitute.com/author/wendy-marsh-9072025-06-06never0.2https://psychopharmacologyinstitute.com/author/timothy-brewerton-9082025-06-06never0.2https://psychopharmacologyinstitute.com/author/jessica-diaz-9092025-06-06never0.2https://psychopharmacologyinstitute.com/author/mohan-gautam-9102025-06-06never0.2https://psychopharmacologyinstitute.com/author/michael-e-thase-9112025-06-06never0.2https://psychopharmacologyinstitute.com/author/lorena-rodriguez-9122025-06-06never0.2https://psychopharmacologyinstitute.com/author/ken-gillman-9132025-06-06never0.2https://psychopharmacologyinstitute.com/author/diana-martinez-9142025-06-06never0.2https://psychopharmacologyinstitute.com/author/david-rosenberg-9152025-06-06never0.2https://psychopharmacologyinstitute.com/author/stephen-marder-9162025-06-10never0.2https://psychopharmacologyinstitute.com/author/andrew-saxon-9172025-06-06never0.2https://psychopharmacologyinstitute.com/author/lauren-b-gerlach-9182025-06-10never0.2https://psychopharmacologyinstitute.com/author/paul-links-9192025-06-06never0.2https://psychopharmacologyinstitute.com/author/brian-miller-9202025-06-06never0.2https://psychopharmacologyinstitute.com/author/melissa-paulita-mariano-9212025-06-06never0.2https://psychopharmacologyinstitute.com/author/carrie-vaudreuil-9222025-06-06never0.2https://psychopharmacologyinstitute.com/author/carlos-h-schenck-9242025-06-06never0.2https://psychopharmacologyinstitute.com/author/amelia-villagomez-9252025-06-06never0.2https://psychopharmacologyinstitute.com/author/christopher-keary-9262025-06-06never0.2https://psychopharmacologyinstitute.com/author/jaroslava-salman-9272025-06-06never0.2https://psychopharmacologyinstitute.com/author/daniel-j-clauw-9282025-06-06never0.2https://psychopharmacologyinstitute.com/author/radwa-hanafy-9292025-06-06never0.2https://psychopharmacologyinstitute.com/author/richard-seeber-9302025-06-10never0.2https://psychopharmacologyinstitute.com/author/horia-batranu-9312025-06-10never0.2https://psychopharmacologyinstitute.com/author/maria-paz-badia-9322025-06-06never0.2https://psychopharmacologyinstitute.com/author/amit-chopra-9332025-06-06never0.2https://psychopharmacologyinstitute.com/author/david-mintz-9342025-06-06never0.2https://psychopharmacologyinstitute.com/author/oliver-freudenreich-9352025-07-03never0.2https://psychopharmacologyinstitute.com/author/kerstina-boctor-9362025-06-05never0.2https://psychopharmacologyinstitute.com/author/sydney-m-lefay-9372025-06-05never0.2https://psychopharmacologyinstitute.com/author/andrea-quintas-9382025-06-10never0.2https://psychopharmacologyinstitute.com/author/scott-zeller-9392025-06-05never0.2https://psychopharmacologyinstitute.com/author/alexis-ritvo-9402025-06-05never0.2https://psychopharmacologyinstitute.com/author/smita-das-9412025-06-05never0.2https://psychopharmacologyinstitute.com/author/franklin-king-iv-9422025-06-06never0.2https://psychopharmacologyinstitute.com/author/helen-tellegen-9432025-06-06never0.2https://psychopharmacologyinstitute.com/author/kristin-raj-9442025-06-06never0.2https://psychopharmacologyinstitute.com/author/chris-aiken-9452025-06-06never0.2https://psychopharmacologyinstitute.com/author/sebastian-malleza-9462025-06-10never0.2https://psychopharmacologyinstitute.com/author/amanda-koire-9472025-06-06never0.2https://psychopharmacologyinstitute.com/author/derick-e-vergne-9482025-06-06never0.2https://psychopharmacologyinstitute.com/author/sagar-v-parikh-9492025-06-06never0.2https://psychopharmacologyinstitute.com/author/scott-crow-9502025-06-06never0.2https://psychopharmacologyinstitute.com/author/tomas-abudarham-9512025-06-10never0.2https://psychopharmacologyinstitute.com/author/kevin-a-sevarino-9522025-07-24never0.2